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As a vital part of the knee joint, the meniscus acts to prevent the degeneration of articular 
cartilage and the onset of knee osteoarthritis (OA). Repairing meniscus injuries in the 
avascular region is still a challenge in orthopaedics. The current primary option is partial 
meniscectomy which can significantly increase the risk of developing knee OA. This unmet 
clinical need has shifted the research focus on the field towards novel cell-based tissue 
engineering approaches. In this thesis, the chondrogenic and immunomodulatory properties 
of regional meniscal cells from degenerative meniscus tissue have been investigated, in 
order to begin to understand more fully the changes in meniscal cells during knee 
degeneration. In addition, progenitor populations from human meniscus tissues have been 
isolated and the cell phenotypes characterised, and their proliferation rate and chondrogenic 
potency for meniscus regeneration analysed as compared their whole mixed population. 
Then moving to cell-based meniscus tissue engineering, a sheep explant model was used 
to examine the feasibility of utilising autologous avascular meniscal cells with a fibrin gel 
delivery system into a clinical grade polyurethane scaffold with the aim of promoting 
meniscus regeneration. A review has also been undertaken of the mid to long-term outcome 
of patients who had received combined autologous chondrocyte implantation (ACI) and 
meniscus allograft transplantation (n=20) or commercial meniscus scaffolds (n=8) treated 
at RJAH Orthopaedic Hospital (Oswestry). 
Herein, it has been demonstrated that both avascular and vascular meniscal cells have 
chondrogenic capacity in vitro and the immunopositivity levels of the integrin markers 
CD49b and CD49c are valuable in distinguishing avascular, vascular meniscus cell and 
chondrocyte phenotypes. Histology of degenerated meniscus showed decreased vascularity 
in “tree-like” transverse collagen fibres, which may indicate that such structures are 




human meniscus contains a meniscal progenitor population in both the avascular and 
vascular regions, based on clonogenicity and chondrogenic differentiation capacity. Results 
suggested that progenitor meniscal cells from vascular regions exhibit superior regenerative 
characteristics which are likely associated with the better meniscal healing properties noted 
in the vascular region of the tissue. The sheep explant experiment proved the feasibility of 
using fibrin gel to deliver autologous avascular meniscal cells in a clinical grade meniscus 
substitute in vitro. Further, the fibrin seeded scaffolds showed increased cell numbers and 
more matrix production compared to scaffolds seeded without fibrin.  
In the clinical study, the data analysed showed for the first time that combining ACI with 
meniscal allograft transplantation or synthetic scaffold transplant to treat patients with 
cartilage defects and meniscal deficiency can provide successful mid-long term clinical 
outcomes, with 10-year survival rates of 71% in the MAT group and 83% in the scaffold 
group. Perhaps combining cells in fibrin in the scaffold could lead to even greater successes 
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1.1 Anatomy of the Meniscus 
1.1.1 Meniscus Gross Anatomy 
The medial and lateral menisci in the knee joint are two crescentic-shaped wedges of 
fibrocartilage located between the femoral condyle and tibial plateau 1. The menisci’s 
superior concave surface allows the convex femoral condyles to articulate, while their 
inferior flat surfaces accommodate the tibial plateau 2. Both play a crucial role in the 
maintenance of a healthy knee. However, there are macroscopic differences between 
the medial and lateral menisci (Figure 1.1).  
In adult humans, the medial meniscus is approximately 40-45mm long and 27mm wide, 
while the lateral meniscus is 32-35mm long and 26-29mm wide. The medial meniscus 
covers less of the corresponding area of the tibial plateau (51-74%) in comparison to 
the lateral meniscus (75-93%) 3. The medial collateral ligament, meniscofemoral 
ligaments, transverse ligament and the anterior and posterior horns maintain the 
stability of the menisci 4. The meniscofemoral ligaments are also known as the 
ligaments of Humphrey and Wrisberg which run from the posterior horn of the lateral 
meniscus to the lateral aspect of the medial femoral condyle 5. The medial meniscus 
displays greater immobility compared to the lateral meniscus as it more firmly attaches 
to the deep medial collateral ligament at the midpoint and continuously attaches to the 





Figure 1.1: Structural view of the human knee meniscus from above.  
The shape and position of medial and lateral menisci are distinct. Reproduced from 
Greis et al. 4 (reprint permission from Wolters Kluwer Health, Inc)  
 
As the vascularity of the meniscus continues to reduce after birth, only 10-25% of the 
peripheral area of the mature meniscus contains vessels and nerves (red-red zone) 7. 
The larger completely avascular zone of the inner meniscus is known as the white-white 
zone. A transition area between the two also exists, which is called the red-white zone. 
The healing capacity of a meniscus has direct relevance to its vascularisation. There is 
evidence that vascularised tissues heal more quickly than avascular tissues. For 
example, there is no blood supply in the cornea and an incision in the avascular cornea 
will heal in approximately 6 weeks, whereas sutures can be removed at 2 weeks from a 
vascular skin incision 8. In the menisci, a tear in the red zone may heal spontaneously, 
but a tear in the white-white region will not heal and will predispose to permanent post-




1.1.2 Extracellular Matrix 
A normal meniscus is primarily composed of water (72%) and collagens (22%), 
interspersed with meniscal cells. The remaining dry weight is composed of 
proteoglycans and matrix glycoproteins 10. These proportions fluctuate depending on 
the age of the individuals and the locations within the meniscus structure 11. 
Collagens 
Collagens play an important role in maintaining the tensile strength of the menisci. They 
make up 75% of the dry weight of the extracellular matrix (ECM) including type I 
collagen, which accounts for over 90%, and variable amounts of types II, III, V and VI 
12. The distribution of each collagen varies in different regions within the tissue. In the 
menisci, type I collagen is predominate with trace amount (<1%) of types III and V in 
the outer two-thirds zone, whereas in the inner zone 60% is collagen type II and 40% 
is collagen type I 13. The collagen fibres in the meniscus run in three layers (Figure 1.2), 
the majority of collagen fibres are orientated circumferentially in the middle layer 
which is ideal for transferring vertical loading into hoop stress. In the superficial layer, 
collagen fibres are oriented in a more radial direction and act as “ties” providing the 
meniscus with rigidity and preventing longitudinal splitting, whereas some radially 






Figure 1.2: Schematic diagram illustrating the collagen fibre ultrastructure and 
orientation within the meniscus  
1, 1st surface layer; 2, 2nd surface layer (radial fibres); 3, middle layer (circumferential 
fibres). Closed arrowheads, radial interwoven fibres; open arrowhead, loose 




Proteoglycans are highly hydrophilic and heavily glycosylated molecules, which 
contribute less than 1% of the meniscus dry weight 16. They are composed of one or 
more glycosaminoglycans (GAGs) chains attached to a core protein. The GAGs in the 
human meniscus are composed of chondroitin-6-sulphate (40%), dermatan sulphate 
(20-30%), chondroitin-4-sulphate (10-20%), and keratan sulphate (15%) 12. The 
amount of proteoglycan in articular cartilage is eight fold higher than that present in the 
meniscus 17. Aggrecan is the major proteoglycan in the meniscus, whereas decorin, 
biglycan and fibromodulin are found in smaller quantities. Proteoglycans in the 




Therefore, proteoglycans are mainly distributed in the meniscal horns and the inner 
two-thirds of the meniscus which is the primary weight-bearing zone 16. 
Matrix glycoproteins 
Meniscal cartilage contains a large range of matrix glycoproteins and their functions 
have not been fully identified. The molecular weights vary from a few kilodaltons (kDa) 
to more than 200-kDa 10. These matrix proteins include the link proteins that stabilize 
proteoglycan hyaluronan aggregates and a 116-kDa protein of unknown function. This 
protein is involved in the formation of a disulphide-bonded complex of large molecular 
weight 19. The adhesive glycoproteins are a subgroup of matrix glycoproteins. These 
macromolecules bind with other matrix components and/or cells, including fibronectin 
and thrombospondin 10,20.            
1.1.3 Cells in the Meniscus 
The cells within a meniscus are regarded as fibrochondrocytes, since they seem to 
possess characteristics of both fibroblasts and chondrocytes 2. They are classified into 
three types according to their shape and location (Figure 1.3). The superficial zone cells 
have a small and round appearance and a recent study suggested that these cells are a 
possible progenitor population with regenerative capabilities 21,22. The outer zone cells 
have an oval, fusiform shape and are described as fibroblast-like cells, whereas the inner 
zone cells appear to have a more rounded shape and are described as chondrocyte-like 
cells 21. The metabolism of the three types of cell is mainly anaerobic with the cells 
having abundant endoplasmic reticulum, Golgi complexes, and few mitochondria. The 






Figure 1.3: Regional cell populations of the meniscus.  
Cells in the red-red region (vascular) are spindle-shaped and more fibroblast-like in 
morphology, while cells in the white-red and white-white region (avascular) are more 
chondrocyte-like. Cells in the superficial layer of the meniscus are round and small. 
Reproduced from Makris et al. 24 (reprint permission from Elsevier) 
 
1.2 Ageing in the Meniscus 
1.2.1 Introduction 
Ageing is an irreversible process, which can be defined as an accumulation of molecular 
and cellular damage over time. It has been suggested that degeneration should be 
considered separate from ageing since degeneration is defined as the failure in tissue 
structure and function which can occur also in young individuals 25. The distinction has 
been accepted in articular cartilage 26 and intervertebral discs 27. Human knee menisci 
similarly exhibit changes associated with ageing. The age-related changes in the 
menisci consist of tissue ageing and cellular ageing (cellular senescence) 25. These 
changes contribute to the pathogenesis of the meniscus, comparable to those seen in 




involved in the ageing of the meniscus. 
1.2.2 Changes in an Aged Meniscus 
Macroscopically, young and healthy menisci appear translucent, white, and with a 
smooth surface, whereas the surface of aged menisci become roughened with 
fibrillation and appears more opaque with a dark yellowish colour (Figure 1.4). These 
colour changes are caused by non-enzymatic glycation similar to age-related changes 
seen in the intervertebral disc 27. In addition, the whole meniscus becomes harder and 
loses its elasticity, although it retains its shape and looks almost normal except for the 
more obvious colour change 29.  
 
Figure 1.4: Schematic diagram of age-related change in the meniscus.  
(A) Macroscopic changes; (B) Increasing cross-link associated changes in collagens; 
Reproduced from Tsujii et al. 25 (reprint permission from Elsevier) 
 
Microscopically, the histology of an aged meniscus (with no or minimal OA) 
demonstrates decreased cell density, with some completely acellular zones being 
identified. Increased Safranin-O staining intensity is observed in the central area of 
avascular zones, as well as mucoid degeneration and the loss of collagen fibres 29. The 




phenotype in meniscal cells during the meniscus ageing process. The earliest age-
related changes in the meniscus are observed in the innermost rim, in which the 
diameter of collagen fibres tends to increase with age 29. A cadaver study showed that 
beyond the age of 50, blood vessels were only present in the outer quarter of an aged 
meniscus. Immunohistochemical (IHC) analyses demonstrated that blood vessels were 
also present in the dense connective tissue insertion, but not in the fibrocartilage itself 
30. In addition, no change in blood supply was shown in degenerative and torn menisci 
compared with a normal meniscus in another cadaveric study (specimens obtained from 
40-80 years of age) 31.  
Collagens 
The collagen content in normal menisci increases from birth to 30 years of age, after 
which the content remains steady until 80 years of age, when there is a gradual decline 
16. The cross-linking of collagen molecules plays a crucial role in physiological and 
pathological processes. Non-enzymatic glycation and deposition of advanced glycation 
end-products (AGEs) increase with age, which is an irreversible process 32. 
Accumulation of AGEs was demonstrated to increase tissue stiffness, as well as 
affecting many cellular processes, such as adhesion of cells to the ECM and cell 
proliferation 32. Pentosidine is known as a mature cross-link and a marker of glycations 
and is found to be significantly increased with age 33. Eventually, menisci with 
increased levels of AGEs become more vulnerable to mechanical damage (Figure 1.4). 
Proteoglycans and fibronectin 
The proteoglycan content in the meniscus appears to increase from birth to maturity, 
and then remains relatively steady. In the adult meniscus, the proteoglycans comprises 
only 2.7 mg/g of the wet weight, compared to 20 mg/g wet weight in adult articular 




meniscus increases with age but does not change in articular cartilage 34. The 
differences in age-related changes observed between the meniscus and articular 
cartilage are likely to be a result of functional and morphological differences between 
the two tissues 25. 
Fibronectin is a glycoprotein that enhances adhesion in the ECM. It has been found to 
decrease with ageing in articular cartilage, which leads to fibrillation 35. Similar 
processes may occur in the meniscus and hence the observed surface roughening and 
fibrillation associated with ageing in the meniscus might similarly be due to a loss of 
fibronectin, but this theory is yet to be proved 25. 
1.2.3 Cellular Senescence in an Aged Meniscus 
Cellular senescence can be described as the onset of irreversible cellular growth arrest, 
whereby cell division ceases as a result of persistent stress. It has been demonstrated to 
play an important role in complex biological processes associated with tissue repair and 
age-related disorders such as OA 36. There are broadly two types of cellular senescence: 
replicative senescence where progressive telomere deterioration is observed and stress-
induced premature senescence which can be induced by a variety of extrinsic factors 
such as ultraviolet light, reactive oxygen species, chemotherapeutics and ionizing 
radiation 36,37. Meniscus cells have the potential for cell division, and cell growth and 
proliferation have been observed in primary culture 38. Although telomere deterioration 
of meniscal cells has not been reported, the senescence of chondrocytes is considered 
to lead to a shift in the balance between ECM synthesis and degradation which 
eventually results in the disruption of tissue homeostasis 39. Moreover, long-term 
compressive stress could also cause premature senescence for meniscus cells 36. In 
addition, increasing cell size has been observed in the aged meniscus, which is a 




reported in chondrocytes in articular cartilage and intervertebral disc cells 40. Thus, 
further evidence is required to prove its role in the meniscus cell cycle. 
1.3 Meniscus Injury and Repair in the Clinic 
1.3.1 Introduction 
Meniscus injuries are the most commonly observed intra-articular knee injury. In the 
United Kingdom, the mean annual incidence of meniscus injury is 60-70 per 100,000 
41. These tears usually happen within the tissue body or the tibial attachment and in 
areas of tissue degeneration 11. There are different types of meniscal tear, such as 
longitudinal tears, radial tears and complex tears. Arthroscopic meniscectomy is the 
most commonly performed orthopaedic surgical procedure. However, partial or total 
resection of a torn meniscus is known to significantly increase the risk of early onset of 
OA 42,43. Therefore, preserving the native menisci where possible is important for the 
long-term function and health of the knee joint. There is a wide variety of meniscus 
repair techniques used in the clinic which will be the focus of the reviewed literature in 
this chapter. 
1.3.2 Meniscal Tears: Aetiology and Classification 
Meniscus injuries can be found in all age groups, although they have been shown to 
have a peak incidence in individuals aged 20 to 29 years, with a male to female ratio of 
between 2.5:1 and 4:1 44. Meniscus injuries are also mostly likely to occur in the right 
knee.  
The aetiological factors involved in meniscal injury vary depending on the patient’s age 
45. More than a third of meniscal tears in young people are caused by twisting sports 
such as American football, basketball, soccer, and skiing; these injuries are referred to 




hyperextension forces, and there is a high risk of an accompanied anterior cruciate 
ligament (ACL) rupture 46,47. Tears in middle-aged and elderly patients usually occur 
as a result of long-term degeneration, which lead to joint swelling, pain and locking; 
these injuries are known as degenerative meniscal lesions 48. There is a high prevalence 
(68-90%) of OA accompanying meniscal lesions as identified in radiographic findings 
49,50. This high correlation brings with it difficulties for the clinical diagnosis of 
symptomatic meniscal tears, since some symptoms may be caused by the OA, while 
others may due to the meniscal tear itself 24. 
Meniscal tears can be divided into two basic types: vertical and horizontal. Vertical 
tears consist of longitudinal, radial and flap tears 51. Different combinations of these 
basic shapes can combine in various patterns to form complex tears (Figure 1.5) 52. 
“Bucket handle” tears (as they are often referred to clinically) are longitudinal and 
vertical tears of the periphery of the meniscus. It is important clinically to locate the 
tear zone exactly since different locations of tears lead to different preferred treatment 
options. The locations can be divided into red-red zone (0-3mm from periphery), red-
white zone (3-5 mm) and white-white zone (>5mm) as demonstrated in Figure 1.6. The 
plethora of treatment regimens available for meniscal tears will be reviewed in the 





Figure 1.5: Examples of Common Meniscal Tears 
Illustration of a normal meniscus (A), and common types of meniscal tears: radial tear 
(B), longitudinal tear (C), horizontal flap (D), vertical flap (E), bucket-handle tear (F), 
oblique/parrot-beak lesion (G), complex degenerative (H), horizontal tear (I), root 
tears (J). Reproduced from Cengiz et al. 52 (reprint permission from Springer Nature) 
 
Figure 1.6: Diagram of meniscal tears locations.  
1: red-red zone; 2: red-white zone; 3: white-white zone. Reproduced from Beaufils et 





Meniscectomy is one of the most widely used orthopaedic procedures globally 42,43. 
However, resection of the meniscus leads to greater stress being applied to the articular 
cartilage, which increases 14-fold the risk of OA after 21 years 43. Similarly, 
arthroscopic partial meniscectomy (APM) has shown poor clinical results at long-term 
follow-up. Partial meniscectomy is usually performed in the avascular zone and has the 
advantage of a quicker rehabilitation period compared to proposed meniscus repair 
techniques. The concept of meniscal preservation has been promoted and researched 
for many years 53. So far, there is no clear consensus in the published literature to 
conclude which meniscal tears should be repaired, but certainly, most experts agree that 
preservation of as much native meniscus as possible will result in better patient 
outcomes 54. It is also thought to be important to preserve the majority of the 
circumferential collagen fibres which are essential to the effective transfer of vertical 
load, hoop stress and shock-absorption 15. 
It is interesting to note that even while the majority of publications indicate the benefits 
of meniscus repair, there is still a considerable gap between what is recommended in 
the literature and what happens in the clinic. Reasons for this may arise from historical 
surgical perspectives: “I always did this operation as it works” and from patient pressure: 
“Rehabilitation of repair is too long, I need to return to sport” 51. 
1.3.4 Repair of Meniscal Tears 
As previously discussed, meniscus repair represents the most ideal solution for 
treatment. However, not all kinds of tear can be repaired. The reference indication for 
repair is usually longitudinal vertical tears in the vascular zone (Figure 1.7). Final 
clinical judgement depends on a surgeon’s experience, the condition of the patient’s 




There are three techniques used for arthroscopic suture repair of the meniscus: outside-
in, inside-out and all-inside. The outside-in technique is passing sutures percutaneously 
through spinal needles across the meniscus rim and the torn meniscus body; then, 
retrieving the sutures under arthroscopic observation, another spinal needle penetrates 
over the meniscus to retrieve the suture end and tie outside the capsule 56. The inside-
out technique involves fixation of a tear by placing sutures from inside the knee to an 
area outside of the joint capsule, then cannulas are used to pass the sutures through the 
joint and across the tear, a small incision is used to retrieve the sutures and tie them off 
directly on the capsule 56. All-inside suture is passing a suture with a suture hook device 
and the suture would be tied intraarticularly 56. For successful meniscal healing, all of 
these techniques need reliable primary fixation 57. Most surgeons prefer all-inside repair 
because of the low risk of neurovascular damage and the short surgical time that is 
required for this procedure 58. Tears in the anterior and middle segments are usually 
repaired by outside-in sutures in conjunction with posterior all-inside sutures. Posterior 
meniscal capsular lesions which contribute to rotational laxity cannot be easily detected 
on the anterior arthroscopic portal 59,60. They are usually exposed by a posteromedial 
approach and fixed by an all-inside hook suture 61. Open meniscus suturing can be 
considerable in horizontal cleavage in young athletes, while traumatic root tears can be 
repaired by trans-osseous pull-out reinsertion 57. 
Additional techniques include puncturing the meniscus with a needle to enhance 
fibrovascular healing in the avascular zone, shaving the parameniscal synovium 46 and 






Figure 1.7: A pyramid schematic describing the repair potential for different types of 
meniscal injury.  
Reproduced from Cengiz et al. 52 (reprint permission from Springer Nature) 
 
1.3.5 Meniscus Allograft Transplantation 
Patients who present with symptomatic knee pain several years after meniscectomy can 
be provided with the surgical option of meniscus allograft transplantation (MAT). The 
first MAT surgery was performed in 1984 in response to the effect of prior 
meniscectomy 63. Many MAT systematic reviews have shown a significant 
improvement in knee function and symptom release in the midterm and long-term 
follow-up after MAT, with acceptable complication and failure rates 64–67. There is a 
consensus that MAT should only be considered in patients with localized pain and a 
stable and well-aligned knee joint. There is no clear evidence, however, to determine 
whether this procedure is chondroprotective. A systematic review based on radiological 




OA, although there is a need for some well-designed randomized control trials to fully 
ascertain the efficacy of MAT 68. 
Several meniscus transplantation systematic reviews have been published. Lee et al. 69 
evaluated 24 studies with clinical outcomes compared between isolated MAT and MAT 
combined with other procedures. No significant differences were found between these 
two groups. However, more data was thought to be needed to draw accurate conclusions 
about the procedures in terms of complication, reoperation and failure rates, as well as 
in verifying the effects of MAT combined with osteotomy and cartilage procedures. A 
systematic review of 12 studies comparing the clinical outcomes of medial and lateral 
MAT has also been undertaken 70. These results showed that lateral MAT provides 
better clinical outcomes compared with medial MAT, with regards to KOOS (Knee 
Injury and Osteoarthritis Outcome Score) and IKDC (International Knee 
Documentation Committee) outcome scores. Moreover, the medial MAT group 
experienced a greater incidence of graft extrusion. Although no significant differences 
were observed between the two groups, the medial MAT patients were more prone to 
failure compared with lateral MAT patients. However, few accurate conclusions can be 
drawn as this study lacked evidence from high-quality prospective randomized trials. 
It is interesting to note that there is a wide variability of terms used to define MAT 
failure in different studies. Some authors have defined failure as no improvement of 
knee function or no patient satisfaction; alternatively, failure can be based on secondary 
arthroscopic findings and magnetic resonance imaging (MRI) parameters. Other 
authors have defined failure as removal of the graft or subsequent knee replacement. 
The differences in descriptions of failure that are used make it difficult to evaluate MAT 
failure for a systematic review. Thus, a Delphi investigation using a specialist panel 




1.3.6 Synthetic Meniscal Scaffolds 
In the last decade, many different types of tissue engineered meniscal scaffolds have 
been developed for meniscus regeneration, with the aim of improving knee joint 
function and delaying the onset OA. These scaffolds are usually porous structures and 
are manufactured using biodegradable materials 72. However, many of these scaffolds 
are still investigated only in vitro or are in the preclinical phase of evaluation. Only two 
synthetic and commercially available meniscus implants are currently used to treat 
partial meniscus deficiencies in the clinic: Collagen Meniscus Implant (CMI®; Ivy 
Sports Medicine, Montvale, NJ) and Actifit® (Orteq Ltd., London, UK) 73. 
CMI® is composed of 97% purified type I collagen isolated from bovine Achilles 
tendon, the remaining portion consists of GAGs which include chondroitin sulphate and 
hyaluronic acid 74. CMI® has been used in the clinic since the year 2000 and it can be 
implanted arthroscopically 75. Its porous structure encourages cellular proliferation and 
differentiation, as well as ECM deposition. As the regenerative meniscal-like tissue 
grows into the scaffold, the scaffold gradually degenerates. A prospective study 
reported that patients receiving this medial meniscus implant showed significant 
improvement in pain, activity level and radiological outcome measures compared to 
individuals treated using partial medial meniscectomy at 10 year follow-up 76. Several 
studies have confirmed these findings, demonstrating similar clinical results 77,78. 
Actifit® is a biodegradable synthetic polymer scaffold composed of 80% 
polycaprolactone (PCL) and 20% of polyurethane (PU). The scaffold was produced 
based on the combination of thermally induced phase separation and crystallization and 
salt leaching using PCL/ 1,4-butanediol/1,4-butanediisocyanate-based PU. The 
compression moduli of scaffold varies from 200kPa to 1MPa with a variation in 




modulus of foam 79. The softer PCL segments contribute to scaffold flexibility and 
initiate hydrolytic degradation at a consistent rate, whereas the more rigid polyurethane 
component provides mechanical strength and serves to make the scaffold more 
biocompatible and uniform in structure 74. The Actifit® scaffold had a very low 
degradation rate which take in place of the presence of water through the hydrolysis of 
ester bonds in the PCL soft segments. The PCL segments is expected to be degraded in 
4-6 years. The polyurethane segments were removed by macrophage phagocytosis or 
became integrated with surrounding tissue. In vitro degradation testing showed that the 
molecular weight of PU decreased 50% while the implant weight was not reduced in 
phosphate buffer at pH 7.4 80. A rabbit study demonstrated that the polyurethane foam 
appeared to be resorbed completely after three years 81. However, no relevant human 
studies have shown the similar results. Actifit® has been developed more recently than 
CMI®, therefore there are no long-term study results that have been reported to-date. 
The safety and feasibility of Actifit® has been demonstrated in short-term outcome 
studies 82, while Dhollander et al.83 reported at 5 years, midterm clinical outcome, 
showing significant improvements of knee joint function and reduced pain in response 
to Actifit®. 
A recent systematic review showed that both CMI® and Actifit® meniscal scaffold 
implantation can significantly improve postoperative outcomes, and those injuries 
treated with associated anterior cruciate ligament reconstruction (ACLR) or high tibial 
osteotomy (HTO) demonstrated better outcomes. However, no significant difference 
between these two groups was reported. The failure rate of the Actifit® scaffold (mean 
follow-up: 40 months) is 9.9%, whereas CMI® (mean follow-up: 44 months) is 6.7%. 
Failure rates are difficult to compare across studies as there are no uniform failure 




main indications and contraindications for CMI® and Actifit® meniscal scaffold 
implantation in the clinic 74. 
Table 1.1: CMI® and Actifit® implantation indications and contraindications 
Indications Contraindications 
• Irreparable meniscal tears with 
partial meniscectomy, 
• Loss of meniscus tissue >25%, 
• Intact circumference rim (except 
area of popliteal hiatus for lateral 
meniscus), anterior and posterior 
attachments. 
• Grade IV degenerative 
osteoarthritis, 
• Posterior cruciate ligament 
insufficiency and posterior knee 
instability, 
• Local infection or osteonecrosis. 
 
1.4 Cell-based Meniscus Tissue Engineering 
1.4.1 Introduction 
As detailed above, successful surgical treatments for meniscal injury in the vascular 
zone have been developed, whereas there are still no satisfactory strategies for meniscal 
injury in the avascular zone, due to its poor self-healing capacity 42. Therefore, to 
improve outcomes in surgical meniscal repair, cell-based regenerative strategies have 
recently received more attention 85. A previous systematic review identified 19 studies 
of preclinical model using cell-based meniscus tissue regeneration 86. All these studies 
used acellular controls to compare different cell sources including MSCs, chondrocytes, 
meniscal fibrochondrocytes. Sixteen studies concluded that cellular based techniques 
demonstrate better outcomes, whereas three studies did not find a superior outcome 
when cells were used. Kon et al. 87 did not find any macroscopic or histology difference, 
but cell-based group was found to have better chondroprotective results. Mizuno et al. 




scoring between experiment and control group. Port et al. 89 added fibrin clots and 
MSCs in suturing longitudinal meniscal tears, but not significant different outcome was 
found when compare with acellular group. No adverse outcomes were reported with the 
implantation of cells. Overall, studies that used cellular techniques suggest that cell-
based techniques produce better results than acellular techniques. However, there is still 
no published consensus to-date regarding which kind of cell is the most appropriate cell 
type for meniscal regeneration.  
1.4.2 Meniscus Cells 
The obvious advantage of using primary meniscus cells (MCs) in meniscal tissue 
engineering strategies is that the MC phenotype will produce an ECM which is most 
like that of the native meniscus 24,90. Baker et al. 91 isolated MCs from ten patients’ 
surgical debris (seven partial meniscectomies and three total knee replacement (TKR) 
from 18-84 year-old donors). Cells were expanded in monolayer culture until passage 
two and seeded onto a PCL scaffold fabricated via electrospinning and cultured for over 
10 weeks. The results showed that fibrochondrocytes from all donors seeded onto 
scaffolds increased the proteoglycan and collagen content within the scaffold over time. 
There was also a strong positive correlation between collagen content and the 
mechanical properties of the scaffolds seeded, but no significant difference was 
observed between the different donor age groups. This study indicated that autologous 
MCs isolated from meniscal tissue debris could be a potential cell source for meniscus 
tissue engineering. However, cell-based meniscus therapy is likely to require a large 
population of cells for seeding scaffolds. To achieve this, an expansion of primary cells 
to passage two or three is often required, which can lead to increased expression of 
collagen I and decreased expression of collagen II and COMP with the number of 




fibrochondrocytes isolated from rabbit menisci on PLDLA/PCL-T scaffolds and 
cultured them for three weeks; at this time point cell-seeded scaffolds and cell-free 
scaffolds were implanted back into the rabbit medial meniscus. Histologically, the 
constructs showed good integration with surrounding tissues and evidence of more, 
predominantly fibrocartilaginous, tissues were observed at 24 weeks compared to 
control groups. Several studies have shown that culturing MCs under hypoxic 
conditions (which is consistent with the microenvironment in the human knee joint) can 
enhance the capacity of MCs to express an ECM-forming phenotype. In addition, 
supplementation with TGFβ1 (transforming growth factor beta 1) and FGF-2 (fibroblast 
growth factor-basic) can further increase this effect up to 10 fold 94–97. These findings 
indicate that MCs may be an ideal cell source for tissue engineering repair strategies 
for the avascular zone of the meniscus. 
1.4.3 Articular Chondrocytes 
Articular chondrocytes (AC) and MCs have similar cell membrane markers and high 
expression levels of collagen and other components of the meniscus ECM 23. ACs have 
been successfully used in ACI for over 20 years 98,99 ACI has been demonstrated for 
safety, efficacy and cost effectiveness as a cartilage repair strategy, having been 
recommended as a treatment option for NHS patients (NICE technical appraisal 477, 
published Oct 2017 https://www.nice.org.uk/guidance/ta477). These similarities and 
advantages make ACs a promising alternative cell source for meniscus repair. Marsano 
et al. 100 demonstrated that ACs produced higher amounts of GAGs and collagens and 
the regenerated tissues were more akin to the inner and outer meniscus tissues compared 
to MCs, fat pad cells and synovial membrane derived cells. Vedicherla et al. 101 
compared fresh chondrocytes (isolated by a rapid digestion method) or minced cartilage 




caprine model. The results showed that both fresh chondrocytes and minced cartilage 
fragments improved the scaffold integration at the tissue-scaffold interface and the 
mechanical strength of the scaffold was increased 4-fold and 2.5-fold, respectively, 
compared with the acellular group. This experiment demonstrated the feasibility of an 
intraoperative one-stage repair strategy, which avoids the high costs and specialised 
expertise (as well as regulatory constraints) involved in cell culturing in good 
manufacturing practice (GMP) laboratories. In addition, single-stage repair surgery 
decreases the risk of infection and other complications for patients. A study comparing 
the capacity of autologous and allogeneic chondrocytes in repairing bucket-handle-
lesions in a porcine model showed no statistically significant differences between the 
cell types 102. Together, these findings indicate the potential for the further study and 
application of chondrocytes in meniscus tissue engineering. 
1.4.4 Mesenchymal Stromal Cells 
MSCs have the potential to differentiate into fibrochondrocytes and the ability to secrete 
a plethora of growth factors which might enhance tissue engineered meniscus repair 
strategies 103. MSCs, such as BM-MSCs, synovium-derived stromal cells (SMSCs) and 
adipose-derived stromal cells (ADSCs), have been widely tested for meniscus healing. 
Bone marrow-derived mesenchymal stromal cells 
Zellner et al. 104 evaluated autologous BM-MSCs or meniscal cells seeded onto 
collagen-hyaluronan scaffolds and implanted into a punch defect rabbit model. Results 
showed that both improved meniscal healing, while BM-MSCs significantly increased 
the gene expression and production of collagen type II compared to meniscal cells. 
Furthermore, gross joint evaluation demonstrated the disadvantage of using autologous 
MCs in the presence of donor site morbidity and the restrictions associated with the 




in-man study that repaired avascular meniscal tears using collagen scaffolds seeded 
with autologous BM-MSCs in five patients. At 24 months’ follow-up, three of these 
patients were asymptomatic with no evidence of recurrent tear according to MRI and 
improvement of knee function scores, whereas two of the patients required a subsequent 
meniscectomy due to re-tear or non-healing. 
Synovial mesenchymal stromal cells 
It was first reported in 1936 that meniscus lesions did not heal without communication 
with the synovium 106. The numbers of MSCs found in synovial fluid was found to 
increase after meniscus injury 107. In rat 108, rabbit 109 and pig 110 meniscal lesion models, 
intra-articular injection of SMSCs has been shown to promote meniscus regeneration 
after resection of the medial meniscus. Nakagawa et al. 111made longitudinal tears in 
the bilateral medial meniscus in 12 micro minipigs, and cultured, passage two SMSCs 
were injected into the unilateral knee. The results from this study showed that meniscus 
healing in SMSCs groups was significantly better than that observed in control (sutured-
only) groups. 
Adipose-derived stromal cells 
It has been demonstrated that the population of MSCs in adipose tissues is 
approximately 500-fold more concentrated than that which resides in bone marrow. 
Akin to BM-MSCs, ADSCs have multilineage differentiation potential and are capable 
of secreting therapeutic growth factors 112. Therefore, ADSCs are also a potential 
candidate cell source for meniscus regeneration. Baek et al. 113 examined different 
human cell sources including inner and outer meniscus cells, ADSCs from the 
infrapatellar fat pad, SMSCs and BM-MSCs for meniscus regeneration in vitro. The 
results of this study showed that ADSCs generated a meniscus-like tissue with higher 




investigated. Ruiz-Ibán et al. 114 reported complete healing and more meniscal 
fibrochondrocytes to be present in an avascular meniscus lesion in a rabbit model after 
the injection of ADSCs (in combination with suturing of the meniscal tear). Moreover, 
better outcome was observed in acute compared to delayed suture. A case report showed 
the successful repair of a torn meniscus accompanied with significant pain reduction by 
intra-articular injection of uncultured autologous ADSCs in the human knee joint 115. 
Together these studies provide evidence that ADSCs might be an effective and non-
invasive cell-based treatment option for meniscus regeneration. 
1.4.5 Co-culture 
Single cell type meniscus tissue engineering strategies have several potential limitations, 
such as insufficient cell numbers, single cell phenotypes (more than one cell type 
resides in the meniscus) and have reported meniscal cell hypertrophy in vitro. Therefore, 
co-cultured cells might improve engineered meniscal properties. Co-culture systems 
include two types: one is a direct contact system whereby different cell types are mixed 
directly; another is indirect whereby different cell types reside in the same system but 
achieve interaction only via paracrine secretions. 
As previously described, collagen fibres determine the tensile strength of the meniscus, 
while GAGs are mainly responsible for the compressive modulus. Articular cartilage 
chondrocytes produce higher levels of collagen type II and GAGs, whereas meniscus 
fibrochondrocytes mainly produce collagen type I. Gunja et al. 116 hypothesised that co-
culturing MCs and ACs on a poly-L-lactic acid (PLLA) scaffold may produce better 
results in resembling various regions of the meniscus. The results from this study 
showed that as the percentage of ACs used increased, the compressive properties of the 
tissue engineered constructs significantly increased.  




also have trophic effects in co-culture systems 117. Cui et al. 118 co-cultured MCs with 
MSCs in different ratios; the results demonstrated that co-culturing MCs and MSCs had 
a synergistic effect on producing functional ECM components of the meniscus and 
inhibits hypertrophy of MSCs during chondrogenic differentiation, as well as 
promoting a meniscal phenotype. The 75% MCs and 25% MSCs co-culture system 
demonstrated the most promising results of the ratios tested. Similar outcomes were 
found when co-culturing MCs and BM-MSCs isolated from TKR 119. McCorry et al. 
120 characterised the fibre formation and matrix production in both MSCs and MCs in 
monolayer culture and 50/50 co-cultures in collagen gels. This group reported that the 
MSC monolayer culture group exhibited higher levels of GAGs with reduced fibre 
diameter, whereas the MC monolayer culture group produced a better collagen 
organisation. However, the co-culture group achieved intermediate levels of GAGs 
production and collagen fibre organisation. Hence, co-culture could be utilised to 
balance the matrix synthesis ability of MSCs and fibre remodelling properties of MCs 
for future applications.  
1.4.6 Combined Autologous Chondrocyte and Bone Marrow Mesenchymal 
Stromal Cell Implantation in the Knee: Two First-In-Man Cases 
Two first-in-man cases treated with combined autologous chondrocyte and BM-MSCs 
implantation for cartilage repair, with 8 and 9 years follow up have been reported in the 
literature as a preliminary output of this PhD thesis 121. In this study patient A (70 years 
of age) and patient B (65 years of age) presented with International Cartilage Repair 
Society (ICRS) grade III–IV multiple cartilage lesions (tibia, femur and patella) and 
underwent a co-implantation of autologous chondrocytes and BM-MSCs between 
February 2008 and October 2009. In brief, chondrocytes and BM-MSCs were 




weeks. Cells were then implanted in combination into cartilage defects, while patient B 
also had a medial Actifit® meniscal scaffold implantation. Both patients were clinically 
assessed preoperatively and postoperatively using the self-reported Lysholm knee score 
and MRI. The actual post-operative scores were compared with scores predicted using 
the Oswestry Risk of Knee Arthroplasty (ORKA) score. The ORKA score 99 is a web-
based app that uses baseline information about the patient’s age and gender, location of 
and the number of cartilage defects and baseline knee function score to predict a 
patient’s risk and time of needing knee arthroplasty. Patient A also had a second-look 
arthroscopy at 14 months after surgery, in which a biopsy of the repair cartilage was 
taken. Both patients demonstrated significant long-term improvement in their knee 
function without complications, with their postoperative Lysholm scores being 
consistently higher than ORKA predictions. Both patients also remained physically 
active without joint arthroplasty at their last follow-up appointments. The latest 
Lysholm scores, 8 years after surgery were 100/100 (Patient A) and 88/100 (Patient B), 
where 100 represents a fully functioning knee joint. Bone marrow lesions (BMLs) 
volume was shown to decrease on postoperative MRI in both patients. Cartilage defect 
area increased in patient A, but declined initially for patient B, slightly increasing again 
2 years after treatment. The biopsy of repair site taken from patient A at 14 months 
postoperatively, demonstrated a thin layer of fibrocartilage covering the treated defect 
site. These two cases suggest that the combination of cultured autologous chondrocytes 
and BM-MSCs appears to confer improved symptoms, at least in these two patients and 
at long-term follow-up. However, despite their improvement in clinical outcome scores, 
physical joint failure as assessed by MRI was seen to progress in both patients. Whether 
this might have progressed with advancing age at a greater rate had the cells not been 




cohorts. In summary, these findings support the hypothesis that autologous BM-MSCs 
stimulate a beneficial host response, reducing pain, perhaps by influencing the 





1.5 Meniscus Scaffolds  
1.5.1 Introduction 
Scaffolds used in meniscus tissue engineering are thought to benefit host tissue 
integration, new tissue formation and remodelling. An ideal scaffold should meet 
certain criteria in both appropriate biomechanical and biochemical properties (Table 
1.2). Table 1.3 summarized and compared the mechanical properties between health or 
degenerated human meniscus and clinical scaffolds including Actifit® and CMI®. The 
current scaffolds can generally be divided into four types: bioabsorbable synthetic 
polymers, hydrogels, biological component scaffolds and decellularised meniscal 
scaffolds 122. The overall objective for the design of these scaffolds is to mimic natural 
meniscus functions and to stimulate the ingrowth of native tissues. 
Table 1.2: Mechanical and biological criteria required for a meniscus scaffold 
Properties Criteria 
Mechanical 
Provide enough biomechanical function to resist compressive or 
tensile modulus 
Maintain shape and stability until enough new tissue regenerates 
Produce mechanical stimulation to promote tissue regeneration 
Biological 
Provide appropriate biocompatibility and nontoxicity to human 
tissues 
Present suitable surface properties for cell attachment and 
proliferation 
Provide appropriate porosity and permeability for growth factors 
and nutrients to reach all of the cells within the scaffold 
Maintain a degradation rate that matches the rate of new tissue 
regeneration and degradation products should be biocompatible 




Table 1.3: the biomechanical and viscoelastic properties of human health or 
degenerate meniscus and clinical scaffold 
 Human (n = 6) Human deg. (n = 6) Actifit (n = 3) CMI (n = 3) 
Stiffness 
[N/mm], cycle1 
8.54 ± 1.87 7.94 ± 2.25 2.83 ± 0.13 4.66 ± 0.35 
Stiffness 
[N/mm], cycle 5 
18.29 ± 2.88 16.59 ± 2.66 3.88 ± 0.17 5,50 ± 0.33 
Residual Force 
[N], cycle 1 
2.99 ± 0.63 2.31 ± 0.69 5.93 ± 0.017 5.15 ± 0.31 
Residual Force 
[N], cycle 5 
4.26 ± 0.54 3.74 ± 0.35 8.18 ± 0.032 5.58 ± 0.32 
Compression 
[%], cycle 1 
19.92 ± 1.36 18.43 ± 055 74.7 ± 4.76 72.8 ± 3.86 
Compression 
[%], cycle 5 
13.58 ± 1.33 14.38 ± 1.14 65.1 ± 3.38 71.89 ± 7.23 
Reproduced from Sandmann et al. 123 (reprint permission from Springer Nature) 
 
1.5.2 Bioabsorbable Synthetic Polymers Scaffolds 
Synthetic polymer materials, such as PU, PCL, polylactic acid (PLA), polyglycolic acid 
(PGA) and polylactic co-glycolic acid (PLGA) have been widely exploited in 
fabricating meniscal scaffolds 122. They have several advantages over other scaffold 
types; these include the ability to be easily shaped, with varied pore sizes, geometry, 
fibre size, mechanical properties and adjustable degradation rates 124. However, these 
materials also have some disadvantages, such as hydrophobic properties and poor 
cytocompatibility. Moreover, their degradation products have been shown to cause 
aseptic inflammation, immune responses and other negative side effects 125. 
Kang et al. 126 reinforced a meniscus-like PGA scaffold by bonding with PLGA (75:25). 
The compressive modulus of the bonded PGA/PLGA scaffold was 28-fold higher than 
the non-bonded scaffold. Allogeneic MCs from rabbits were seeded onto scaffolds and 
cultured in vitro for 7 days and then implanted into medial meniscus-deficient rabbit 




the formation of abundant proteoglycan and collagen networks. However, lower 
collagen content and aggregate modulus were observed when compared to the native 
meniscus. 
PCL has indicated its potential utility due to its high tensile modulus, the promotion of 
cell attachment and proliferation, material plasticity and a slow degradation rate 24,127. 
Zhang et al.128 used PCL meniscal scaffolds fabricated by 3D printing and seeded them 
with BM-MSCs, constructs were then implanted into a rabbit model of meniscal 
deficiency At 12 and 24 weeks postoperative evaluations, the cell-seeded group showed 
significantly better results in fibrocartilaginous tissue regeneration, levels of cartilage 
degeneration on the tibia and femur and had a higher tensile compressive modulus 
compared with the cell-free group.  
Multiple synthetic polymers can be mixed in suitable proportions to enhance their 
compressive, tensile and shear modulus, as well yas their cell-attachment properties. As 
described previously, meniscus substitution Actifit® (20% PU and 80% PCL) has 
already shown promising outcomes in the clinic. “Meniscus-like” tissue ingrowth was 
also observed at two years post-Actifit®-implantation in canine models 129. 
1.5.3 Hydrogels 
Hydrogels have been widely investigated for use in meniscus scaffold engineering. 
Hydrogels are a crosslinked network of hydrophilic natural or synthetic polymer chains. 
A large proportion of the hydrogel content is water, (often >90%) 72. Hydrogels possess 
high levels of permeability, good biocompatibility and inherent biodegradability. They 
can be categorised as natural, synthetic and natural/synthetic hybrid materials. Natural 
polymers have more desirable biological properties and synthetic polymers tend to 




The natural polymers for hydrogels, in the main part, consist of two types: natural 
proteins and polysaccharides. Natural proteins, such as fibrin 131 and gelatin 132 have 
been most widely studied. Polysaccharides include alginate 133, chitosan 134 and 
chondroitin sulphate 135 and these have also been developed either alone or mixed with 
other materials. 
The most widely exploited synthetic hydrogel for meniscus tissue engineering is 
polyvinyl alcohol (PVA). Its biocompatibility and viscoelastic properties are 
comparable to meniscus tissues 130. To improve further the mechanical properties of 
PVA hydrogels, recent studies have developed fibre reinforcement with ultrahigh 
molecular weight polyethylene 136,137 and modification with sodium sulphate 138,139. 
Hydrogel materials play an important role in supporting relevant cell populations for 
meniscus regeneration, ‘plugging the gap’ in meniscal lesions and retaining bioactive 
molecules which are crucial for meniscus healing 130. 
1.5.4 Biological Component Scaffolds 
Biological component scaffolds can be classified as ECM related and biopolymer 
scaffolds. ECM component scaffolds are derived from natural tissues and include 
collagens, proteoglycans and elastin 72. Different combinations of these molecules have 
been used, such as collagen-GAGs or combinations of different types of collagen. 
Nanofibre electrospinning, anisotropic deposition and crosslinking methods have been 
used to fabricate collagen scaffolds. These methods can strengthen the ECM scaffolds 
so that they are comparable in strength to synthetic polymer scaffolds. Moreover, the 
ECM scaffolds can provide a natural environment and bioactivity for seeded cells. The 
CMI® scaffold has been used in the clinic for meniscal implants and belongs to this 
ECM scaffold grouping. CMI® has been shown to significantly relieve pain and 




human BM-MSCs onto CMI® scaffolds and placed these into a bioreactor system. 
Perfusion and biomechanical stimulation were applied to the scaffolds and results 
showed there to be enhanced cell proliferation under continuous perfusion and 
improved differentiation under mechanical stimulation. 
Other recent studies have focused on making biopolymers, such as silk fibroin (SF) 
which is derived from silkworms. SF is known to possess attractive biocompatibility 
and mechanical properties. Pillai et al. 141 developed a scaffold using 3:1 SF and PVA 
reinforced with 3% autoclaved eggshell membrane (AESM) and implanted these 
scaffolds into a meniscal deficiency rabbit model. This SF-PVA scaffold showed a 
similar magnitude of compressive and dynamic properties as compared to the natural 
human meniscus. IHC analyses demonstrated its biocompatibility with minimal 
inflammatory response. Mandal et al. 142 built a three-layered silk meniscal scaffold by 
using a salt leaching and freeze-drying method. The scaffolds were seeded with 
chondrocytes and cultured for 28 days. Results showed an increased production of 
GAGs and collagens similar to those found in native meniscus tissues. Together these 
studies suggest that SF is a promising natural material for meniscus tissue engineering 
applications. 
1.5.5 Decellularised Meniscal Scaffolds 
Recently, decellularised ECM meniscus scaffolds have drawn a great deal of interest as 
a method to improve meniscus engineering. Decellularised scaffold composed of 
natural ECM components and structures, but without immunogenic cells are typically 
derived from allogeneic or xenogeneic tissues 143. Decellularisation causes minimal 
immunogenicity and preserves the ECM, which can protect its biological function. 
Combinations of physical (e.g. freeze-thaw cycles), chemical (e.g. acids or detergents, 




and trypsin) agents are used to lyse cells by solubilizing the cytoplasm and membranes 
144. In general, the procedure for meniscus regeneration using decellularised ECM 
scaffolds involves decellularisation of a meniscus and its reseeding with appropriate 
cell types (Figure 1.8). 
 
Figure 1.8: Schematic representation of the cell-loading of a decellularised ECM 
meniscus scaffold.  
Reproduced from Chen et al. 144 (reprint permission from Springer Nature) 
 
Maier et al. 145 developed a decellularised ovine meniscus using enzymatic methods 
including trypsin, collagenase A, protease and EDTA treatments. Histological and IHC 
analyses showed complete cell removal and high histocompatibility. However, the 
GAG content was shown to be significantly reduced. Chen et al. 146 investigated the 
potential of a decellularised porcine meniscus using an acid-based method to 
decellularise the tissue. They found that formic acid decreased the meniscal DNA 
content most efficiently compared to other acids, without any adverse effect on GAGs 
content. These scaffolds were seeded with human primary chondrocytes and after 




populations increasing 10.1-fold. GAGs and total collagen increased by 572.34% and 
301.11% respectively, from day 7 to day 21. Finally, the decellularised ECM scaffolds 
were implanted subcutaneously into rats and no sign of inflammation was observed 
after 28 days. This study indicated that this decellularised allogeneic meniscus did not 
cause a significant detectable immune response. Decellularised scaffolds are highly 
bioactive and provide a natural microenvironment for meniscus repair, although 
disadvantages to their use have been discussed, which include the poor mechanical 
properties observed in some studies and the deficiency of suitable menisci for 
decellularisation 144. 
1.6 Aims of PhD Project 
From our literature review, we scoped that the histological changes of meniscus from 
normal to degeneration has well established. However, to our knowledge, the cell 
phenotype alteration in degenerated meniscus was still not clear. In addition, few 
studies suggested that meniscus contains a group of progenitor population which 
involves in the meniscus healing process. There is no clear evidence characterize the 
progenitor population in meniscus and their origins. This special cell fraction could be 
a potential treating target in the future. In terms of cell-based meniscus tissue 
engineering, it has been widely explored including cell sources and scaffold in vitro and 
preclinical model based on our literature review. However, the application in use of 
cell-based strategy in treating meniscal lesions in clinic is still under exploration stage. 
The overall purpose of this PhD project was to provide data that would advance 
meniscus tissue regeneration approaches using cell-based tissue engineering. This was 
accomplished through the following basic research and clinical projects: 




phenotypes and characterising potential therapeutic cells): 
(1) Characterisation of the regional meniscal cells and chondrocytes phenotypes 
and their chondrogenic differentiation capacity from OA donor matched tissues. 
Investigations were also conducted to analyse the histological features of the 
OA meniscus (Chapter 3). 
(2) Determination of progenitors in the avascular and vascular region of the 
meniscus and a comparison of their chondrogenic capacity with their 
comparator whole mixed populations (Chapter 4). 
(3) Examination of the feasibility of delivering autologous avascular meniscal cells 
using a fibrin gel into a clinically used polyurethane scaffold to promote 
meniscus tissue regeneration in a sheep explant model (Chapter 5). 
Clinical study (focussed on analysing one of the current combinatorial cell-based and 
tissue engineering approaches): 
(1) A review of the clinical outcomes of patients who had combined ACI with 
meniscus allograft transplantation or a polyurethane scaffold implantation 









2.1 Cell isolation, cell culture and cell preservation 
2.1.1 Obtaining patient consent and samples 
All tissue samples used in this study were obtained from individuals undergoing knee 
surgery at our centre, the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH). 
Fully informed consent was obtained from patients with ethical approval given by 
National Research Ethics Committee Northwest Liverpool East (11/NW/0875) 
(appendix I). All patient consents were obtained prior to surgery. All tissue samples 
were kept in sterile pots and stored at 4℃ prior to use and those for further cell culture 
were processed within 24 hours. 
2.1.2 Avascular & vascular meniscal cells and chondrocyte isolation 
Each sample was washed in phosphate buffer saline (PBS, Gibco - Thermo fisher 
Scientific, USA) three times and photographed before processing. Macroscopically 
healthy meniscus and full depth cartilage from TKR samples were removed with a 
sterile scalpel for cell isolation. The meniscus was dissected into the inner (avascular 
zone), middle and outer (vascular zone) as shown in Figure 2.1. The middle portion was 
discarded such that only the definite vascular and avascular zones were studied. A 
section of the meniscus adjacent to that used for cell culture experiments was harvested 
for histology. Meniscal cells and chondrocytes were isolated following a protocol 
established in our GMP manufacturing facility for chondrocytes 147. Meniscus and 
cartilage tissues were digested in type II collagenase (245U/ml; Worthington, USA) in 
Dulbecco’s Modified Eagle Medium (DMEM)/ F12 (1:1) (Gibco, USA) and 1% 
penicillin-streptomycin (P/S) (ThermoFisher Scientific, USA) for 16 hours at 37°C. 
The suspension was passed through a 40 μm cell strainer and pelleted at 800g for 10 






Figure 2.1: Schematic diagram of the process used for meniscus dissection 
The central part of the macroscopically “normal” meniscus was longitudinally divided 
into three parts: the inner third was used to extract avascular meniscal cells, the outer 
third for the extraction of vascular meniscal cells. The adjacent perpendicular section 
composed of both inner and outer regions was used for histological grading. 
 
2.1.3 Cell culture in monolayer and cell passaging 
Meniscal cells and chondrocytes were seeded into tissue culture flask at a density of 
5x103 cells/cm3 (passage 0) in complete medium (DMEM/F12 (Gibco, USA), 10% (v/v) 
foetal bovine serum (FBS) (Gibco, USA), 1% (v/v) P/S (ThermoFisher Scientific, 
USA), 62.5 μg/ml L-ascorbic acid 2-phosphate (Sigma-Aldrich, USA)). Cells were 
incubated at 37°C, 5% CO2 for 4-5 days to allow cell adherence, after which media 
were replenished every 2-3 days. After reaching 70-80% confluence, cells were washed 
with PBS and incubated with pre-warmed 0.05% trypsin/EDTA (Gibco - Thermo fisher 
Scientific, USA) at 37°C for 5 minutes. Cells were observed under a light microscope 




was neutralised with an equal volume of complete medium and cell suspension was 
centrifuged for 10 minutes at 800 g. The supernatant was discarded and the cell pellet 
was resuspended in 1ml of complete medium. A cell count was performed, and cell 
viability was recorded. Cells were reseeded at a density of 5x103/cm2 in tissue culture 
flasks. The trypsinisation, counting and reseeding process was referred to as one 
passage increase. 
2.1.4 Cells cryopreservation 
Cells required for further experiments were banked by cryopreservation. Following 
cells trypsinisation and counting, cells were resuspended in 10% (v/v) dimethyl 
sulfoxide (Sigma-Aldrich, USA) in FBS at 1x 106 cells/ml. The suspension was gently 
pipetted into cryovials and stored in a Mr. FrostyTM freezing container (Thermo 
Scientific, UK) filled with isopropanol (IPA) at -80°C for 24 hours. The cryovials were 
transferred to liquid N2 at -196°C for long term storage. 
2.2 Meniscal progenitor cells 
2.2.1 Meniscal progenitor cells isolation protocol 
A fibronectin adhesion assay was used to isolate meniscal progenitor cells from the 
avascular and vascular regions. This protocol has been well established to extract 
chondroprogenitor cells from cartilage 148. Progenitor cells, showing the characteristics 
of stem cells, are selected due to their high expression of β1 integrins on the cell surface 
and rapid adhesion to ECM proteins, such as fibronectin 149. 
The definite avascular and vascular meniscal cells and full-depth macroscopically 
normal articular cartilage from femoral condyles were donor matched, being obtained 
from the same individual. Samples were digested by sequential pronase (70 U/ml, 1 




medium. All three cell types (avascular and vascular meniscal cells and chondrocytes) 
were cultured under two conditions. The first group was a mixed population of cells 
including avascular meniscal mixed cells (MAvas), vascular meniscal mixed cells 
(MVas) and mixed chondrocytes (MChs), which were plated at a density of 5000 
cells/cm2. The second group was progenitor cells including avascular meniscal 
progenitors (PAvas), vascular meniscal progenitors (PVas) and chondroprogenitors 
(PChs), which were subjected to a fibronectin adhesion assay as previously described 
148. Briefly, 6 well plates were coated with 10µg/ml fibronectin (Sigma, UK) in PBS, 
containing 1mM MgCl2 and 1mM CaCl2 overnight at 4℃. Each isolated mixed 
population of cells (1000 cells/well) was seeded onto 3 wells in coated plates for 20 
mins at 37℃ in complete medium. After 20 minutes, medium and non-adherent cells 
were removed. Fresh complete medium was added to the remaining adherent cells and 
incubated at 37°C, 5% CO2. 
2.2.2 Cell-IQ® live imaging of progenitor colonies 
After three days culture in 6 well plate, progenitor cells were sent in Cell-IQ® phase 
contrast Live Imaging Platform (CM Technologies, Tampere, Finland) to monitor 
colony formation. The Cell-IQ® system is a self-contained cell culturing instrument 
including environmental control with phase-contrast microscopy and an automation 
system for repeat imaging of the same location over a defined timescale (Table 2.1). 
The system consists of an automated optics module (Figure 2.2) and an integrated 
incubator with two gas flow controllers 150. The imaging system allows continuous 
imaging of, for example, cell number, motility and morphology in two plates which are 
controlled under an integrated plate holder. Spare wells and surrounding areas in 6 well 
plates were filled with distilled water to keep the plate humidified. At least one colony 




The recorded images were transferred to the Cell-IQ® analyser (CM Technologies, 
Tampere, Finland) to measure the cell number of each colony every 30 minutes.  
Table 2.1: The Cell-IQ® components 
Cell-IQ® Vision System 
Phase contrast 
microscope 
Environment control Automation 
▪ Light source 
▪ Optics 




▪ Incubation gas 
control 
▪ Automated cell 
imaging for selected 
positions 
▪ Label free cell 
analysis based on 
morphology 
▪ Motorized XYZ 
translation stages 






Figure 2.2: Schematic diagram of the automated optics module and monitoring 
system.  
The optics module consists of a digital 768 × 576-pixel camera integrated with a phase-
contrast microscope and a phase contrast objective with 200mm optics, built onto a 
motorised z-direction movement stage. The sample plate was allowed to motorise on 
an xy-direction movement stage to capture images from different locations. A green 
LED light (530 nm) provides an illumination source for high quality phase-contrast 
images. Reproduced from Narkilahti et al. 150 (reprint permission from Springer Nature) 
 
2.3 Growth kinetics in monolayer culture 
Cell proliferation rate was determined by population doubling times (PDT).  PDT was 
calculated using the following formula:  








number of cells seeded initially and harvested, respectively. 
2.4 Detection of cell surface markers by flow cytometry 
2.4.1 Flow cytometry introduction 
Flow cytometry uses a sophisticated instrument that rapidly analyses multiple physical 
characteristics of a single cell (or particles) as the cell suspension flow through a 
measuring device. The basic working principle of flow cytometry is measuring light 
scattering and fluorescence emission which is generated by a laser beam striking the 
moving cells or particles (Figure 2.3). The patterns of light scattering include forward 
scatter (FSC) and side scatter (SSC). FSC light is diffracted by cells and collected along 
the same path as the laser beam to identify cell size, whereas SSC light is a measurement 
of refracted light at approximately 90 degrees to the laser beam to identify cell 
granularity or internal complexity, as well as the fluorescent light reflected from 
fluorescent-labelled antibodies (Figure 2.4). Detectors capture the emitted light, which 
is converted into electronic signals by a computer for analysis. 
 
Figure 2.3: Illustration of the working principle of a flow cytometer.  





Figure 2.4: Flow cytometry light scattering. 
Forward scatter is proportion to size while side scatter is proportional to the cell 
granularity or internal complexity. Reproduced from Adan et al. 151 (reprint permission 
from Taylor & Francis) 
 
2.4.2 Preparation for flow cytometry 
A profile of cell surface markers were selected based on the International Society for 
Cellular Therapy (ISCT) criteria for MSC phenotype152, chondrogenic potency 153,154–
156 and integrin families 157,158, which were analysed via multi-colour channel flow 
cytometry. Details of fluorochrome, isotype control and clones are listed in Table 2.2. 
Different panels which are specific for individual experiments are listed in the 
experimental design of each chapter.  
Experiments were conducted on monolayer cultured cells at passage 0 (P0) or prior to 
chondrogenesis. Briefly, 160,000 cells were resuspended in 1ml 2% (w/v) bovine serum 
albumin (BSA, Sigma-Aldrich) in PBS and 10% (v/v) human IgG (Grifols, Spain) and 




eliminate non-specific binding. The suspension was centrifuged at 500g for 5 minutes 
and the cell pellet was resuspended in 2% (w/v) BSA and aliquoted evenly in flow 
cytometry tubes (100μl per tube). Fluorochrome conjugated antibodies against the 
ISCT MSC criteria including CD14, CD19, CD34, CD45, CD73, CD90, CD105, HLA-
DR (BD Biosciences, Oxford, UK), chondrogenic potency markers including CD44, 
CD151, CD166, CD271 (BD Biosciences, Oxford, UK) and for the integrins including 
CD29, CD49b, CD49c (BD Biosciences, Oxford, UK), were added to tubes according 
to the layout depicted in Figure 2.5. Cells were incubated with antibodies for 30 minutes 
in the dark at 4°C and washed with 2ml of 2% (w/v) BSA and centrifuged at 350g for 
8 minutes. Supernatant was carefully discarded and the pellets were resuspended in 
300μl of 2% (w/v) BSA. Samples were analysed using a FACS CantoTM II flow 





Table 2.2: Cell surface molecules for flow cytometry 
Marker Fluorochrome Isotype 
control 
Clones Description 
CD14 152 PerCP-Cy5.5* IgG2b MφP9 Monocyte differentiation 
antigen, LPS-receptor 
CD19 152 BV421* IgG1 HIB19 B lymphocytes antigen 
CD29 157 APC* IgG1 MAR4 Integrin β1, cell adhesion 
CD34 152,159 APC IgG1 581 Hematopoietic progenitor 
cell antigen 
CD44 156 PerCP-Cy5.5 IgG2b G44-26 Hyaluronate Receptor 
CD45 152 PE* IgG1 HI30 Protein tyrosine 
phosphatase receptor type C 
CD49b 158 BV IgG2a 12F1 Integrin α2 
CD49c 158 PE IgG1 C3 II.1 Integrin α3 
CD73 152 BV421 IgG1 AD2 5'-nucleotidase 
CD90 152 PE IgG1 5E10 Thy-1 
CD105 152 APC IgG1 266 Endoglin 
CD151 155 PE IgG1 14A2.H
1 
Raph blood group 
CD166 154 BV421 IgG1 3A6 Activated leukocyte cell 
adhesion molecule 
(ALCAM) 
CD271 153 BV421 IgG1 C40-
1457 
Low-affinity nerve growth 
factor receptor 
HLA-DR 152* APC IgG2b TU36 Human leukocyte antigens-
DR 
* PercP-Cy5.5: Peridinin-chlorophyll-protein-Cyanine5.5, BV421: Brilliant Violet 421, 






Figure 2.5: Diagram of the combination of fluorochrome conjugated antibodies 
assessed via flow cytometry.  





2.5 Three-dimensional pellet culture for chondrogenic 
differentiation 
An established 3D pellet culture system was used to assess the chondrogenic potency 
of donor-matched avascular and vascular meniscal cells and chondrocytes 160. 2 x 105 
cells were centrifuged at 350 g for 8 minutes into a cell pellet in sterile 1.5 ml 
microcentrifuge Eppendorf tubes, supplemented with DMEM/F12, P/S (1%), insulin-
transferrin-selenium (ITS) (1%), L-ascorbic acid-2-phosphate (1 mM) (Sigma-Aldrich), 
dexamethasone (100 nM), sodium pyruvate (1 mM) (Sigma-Aldrich) and TGF 
β1( PeproTech, London, UK) (10 ng/ml). 
2.6 Biochemical analyses for chondrogenesis within the pellets 
2.6.1 Papain digestion of chondrogenic pellets 
After 28 days in culture, pellets were digested in papain to release GAGs and DNA. 
The papain digestion buffer was composed of 50mM sodium phosphate (BDH), 20 mM 
EDTA (Sigma-Aldrich), 20 mM N-acetyl cysteine (BDH) and adjusted to pH 6.0. 
Papain was added to the buffer to reach the final concentration of 125µg/ml. Each pellet 
was digested in 200µl of the papain solution at 60°C for 3 hours. The digestion samples 
were vortexed every 30 minutes. Samples were centrifuged at 1000g for 5 minutes and 
stored at -20°C prior to use. 
2.6.2 Dimethylmethylene blue assay (DMMB) 
The total GAG content in pellets was measured by 1,9-dimethylmethylene blue 
(DMMB) assay 161. The DMMB dye solution was prepared by adding 4mg DMMB 
(Sigma, Poole, UK), 0.76g glycine (Sigma, Poole, UK) and 0.595g sodium chloride 
(NaCl) into 250ml distilled water, followed by adjusting to pH 3.0 using 10M 




Sigma-Aldrich) from bovine trachea in distilled water (stock: 1 mg/ml) and diluted into 
standards of 0, 0.025, 0.05, 0.075, 0.1μg/ml. 50μl of samples or standards were added 
into 96 well plates in triplicate, with 200μl of DMMB dye solution. The absorbance 
results were read immediately at A530nm and A590nm on a FluorStar Omega microplate 
reader (BMG Labtech, Ortenberg, Germany). The standard curve was plotted using the 
following equation:  
(A530nm/A590nm) −⁡(A530nm⁡blank/A590nm⁡bank) 
where A530nm, A590nm is the absorbance of samples (or standards) at 530nm and 
590nm; A530nmblank, A590nmblank is the absorbance of 0μg/ml standard at 530nm 
and 590nm. The total GAGs content of each pellet was calculated using the standard 
curve equation. 
2.6.3 DNA Assay 
The PicoGreen® dsDNA Assay Kit (Thermo fisher Scientific, Massachusetts, USA) 
was used to determine DNA content in pellets following the manufacturer’s instructions. 
PicoGreen® is a fluorescence probe that binds double-stranded (ds) DNA which forms 
a highly luminescent complex compared with the free dye in solution 162. 1 x TE buffer 
(10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was made from 20 x TE stock supplied in the 
PicoGreen kit. PicoGreen® reagent was diluted (1:200) in 1 x TE buffer and protected 
from light. Standards were prepared by diluting lambda DNA (100μg/ml) with 1 x TE 
buffer at a final concentration of 2μg/ml. The stock solution was then used to create 
standards at concentration of 0, 25, 50, 100, 200, 300, 400, 500 and 1000ng/ml. 100μl 
of samples or standards were pipetted into 96 well plates in triplicate, with 100μl of 
PicoGreen reagent. The microplate was covered with foil and incubated at room 
temperature for 4 minutes after which the fluorescence value was read at excitation (480 




value of the blank was subtracted from each sample and the DNA concentration was 
determined using the standard curve. Finally, the total GAG contents in the 
chondrogenic pellets were normalised to the DNA content of each pellet. 
2.7 RNA extraction and Quantitative Real-Time Polymerase 
Chain Reaction (qRT-PCR) 
Avascular and vascular meniscal cells and chondrocytes (2 x 105 cells) cultured in 
monolayer (P0) or chondrogenic pellets were resuspended in 350μl RLT lysis buffer 
(Qiagen, Hildner, Germany) containing 1% (v/v) β-mercaptoethanol (Sigma, Poole, 
UK), followed by snap freezing in liquid N2 and storage at -80 °C in 1.5ml Eppendorf 
tubes for subsequent RNA extraction. 
2.7.1 mRNA extraction 
A RNeasy Mini Kit (Qiagen, Hilden, Germany) was used for mRNA extraction from 
cells or pellets according to the manufacturer’s instructions. After samples were thawed, 
350μl of 70% ethanol (Sigma, Poole, UK) in RNase free water (Sigma, Poole, UK) was 
mixed with each sample and transferred to a spin column placed in a 2ml collection 
tube. The collection tube was centrifuged at 10,000g for 1.5 minutes. RWI buffer (700μl) 
and RPE buffer (500μl) were used to perform one and two washes of the mRNA 
respectively and centrifuged at 10,000g for 1.5 minutes. 50μl of RNase free water was 
added and centrifuged at 10,000g for 1.5 minutes to elute the mRNA. The final volume 
was collected in a 0.5ml Eppendorf tubes and stored at -80 °C. 
2.7.2 mRNA reversed to cDNA 
mRNA was converted to cDNA using a high-capacity cDNA Reverse Transcription kit 
(Applied Biosystems, California, USA). 25μl of mRNA sample was transferred into a 




dNTP mix, 5μl of random primers, 2.5μl of multiscribe reverse transcriptase (50 U/μl) 
and 10.5μl of RNase free water. All steps were performed on ice. The tubes were placed 
in a thermocycler (Techne, Cambridge, UK), which was pre-programmed to 25 °C for 
10 minutes, 37 °C for 2 hours and a final holding step of 4 °C. Samples were stored at 
-20 °C until further use. 
2.7.3 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was performed using SYBR Green® (Applied Biosystems, California, USA) 
which was specifically binds to dsDNA to monitor gene amplification. 2μl of cDNA 
sample was added into a 96-well PCR reaction plate in triplicate. Subsequently, a 
reaction mixture consisting of 12.5 μl SYBR Green Master Mix (Taq DNA polymerase, 
dNTP and SYBR Green dye), 2.5 μl of primers for the target gene and 8 μl of RNase 
free water were added into each well. The description of target genes is listed in Table 
2.3. The plate was then sealed using an optical adhesive film (Applied Biosystems, 
California, USA) and placed in the Quant Studio3 Real-Time PCR machine (Applied 
Biosystems, California, USA). The PCR machine was configured to run the following 
temperature protocol: activation of SYBR Green (10 minutes, 95°C, each for 1 cycle); 
40 repeated cycles of denaturation of cDNA (10 seconds, 90°C,), annealing (30 seconds, 
55°C) and extension (34 seconds, 72°C); dissociation (10 seconds, 94°C; 30 seconds, 
55°C; 10 seconds, 94°C, 1 cycle). The Quant Studio Design and Analysis Software 
(Applied Biosystems, California, USA) was used to determine the cycle threshold (CT) 
values, which is the cycle number that the fluorescence generated within that reaction 
crosses the fluorescence threshold. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) were used as 
reference genes. The relative gene expression was calculated using the comparative CT 




Table 2.3: Primers used for qRT-PCR 
Gene: Official full name Gene ID (NCBI) 
Reference gene 
HPRT1 Hypoxanthine phosphoribosyl transferase 1 3251 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 2597 
Chondrogenic markers 
ACAN Aggrecan 176 
COL2A1 Collagen type 2 alpha 1 1280 
SOX9 SRY-box transcription factor 9 6662 
De-differentiation markers 
COL1A2 Collagen type I alpha 2 chain 1278 
Hypertrophic markers 
COL10A1 Collagen type 10 alpha 1 1300 
MMP1 matrix metallopeptidase 1 4312 
 
2.8 Histological analysis 
2.8.1 Cryosection of chondrogenic pellets 
After 28 days in chondrogenic culture, 3 pellets from each cell population were washed 
with PBS and imaged under a Hamamatsu digital camera (C4742-95). Pellets were then 
placed on filter paper and snap frozen in liquid nitrogen cooled hexane and stored at -
80 °C until needed. Frozen pellets were mounted onto a pre-cooled chuck with 




(CellPath, Newtown, UK). Pellets were sectioned at a 7 μm thickness using a cryostat 
(Bright, Luton, UK; Model: OTF) and collected on poly-L-lysine coated slides. 
Sections were stored at -20°C for future staining. 
2.8.2 Wax embedding and sectioning of human meniscus tissue and sheep 
meniscus explant 
Human meniscus tissue obtained from TKR patients or sheep meniscus explants 
samples were dissected as described in chapter 2.1.2. The cross-section of meniscus 
was fixed in 10% neutral buffered formalin for at least 48 hours at room temperature. 
These samples were then processed by the histopathology laboratory at RJAH 
Orthopaedic Hospital as follows. Samples were put in cassettes and placed in the 
following solutions, for one hour each: 70%, 90%, 95%, 100%, 100% and 100% of 
methylated spirit (IMS, Gent Medical, York, UK), followed by immersing the samples 
twice in xylene for one hour prior to immersing twice in Fibrowax® (VWR, 
Pennsylvania, USA) at 65°C for 1 hour. The samples were mounted in a mould with 
hot Fibrowax and solidified on a cold platform for 30 minutes. The mould was detached 
from the wax block and sectioned at a 5 μm thickness on a microtome (Leica, Wetzlar, 
Germany). Sections were then collected onto slides in a warm water container and dried 
at 37°C for 24 hours. 
2.8.3 Haematoxylin and Eosin (H&E) staining of human meniscus sections 
The H&E staining is used to assess the general morphology of the meniscus tissues 
dervied from TKR patients. Haematoxylin is a basic dye that is positively charged and 
so stains the acidic tissue and cell structure (basophilic) purplish blue, whereas eosin is 
an acidic dye, that being negatively charged, stains the basic structures (acidophils such 
as cytoplasm and ECM) into pink or red 164. 




minutes and rehydrated in 100% (x2), 90% and 70% isopropanol for 2 minutes each, 
followed by rinsing twice in distilled water for 3 minutes. All slides were flooded with 
Harris’s Haematoxylin (ATOM Scientific, Cheshire, UK) for 5 minutes and rinsed with 
tap water for 5 minutes to allow sections to turn “blue”. Slides were then flooded in 1% 
eosin for 30 seconds and washed in tap water. Slides were dehydrated through an 
ascending sequence of concentrations of isopropanol: 70%, 90%, 100% x2 for 2 
minutes each, after which slides were transferred to clear in xylene twice for 5 minutes. 
Slides were mounted using Pertex (Histolab, Othenburg, Sweden) and left to dry for at 
least 1 hour. 
2.8.4 Toluidine blue staining of chondrogenic pellets 
Toluidine blue is a basic thiazine metachromatic dye used to visualise the presence of 
GAGs 164. To perform toluidine blue staining for chondrogenic pellets, cryosections 
were thawed at room temperature. Slides were then flooded with 1% toluidine blue 
(BDH Lab Supplies, Poole, UK) for 30 seconds and rinsed in running tap water to 
remove the excess dye. The stained slides were then air dried and mounted using Pertex 
with coverslips. Once dry, pellets stained with toluidine blue were viewed under a Leitz 
Diaplan light microscope (Leitz, Stuttgart, Germany) and imaged using the Nikon DS-
Fi1 camera (Nikon, Tokyo, Japan). 
2.8.5 Immunochemical staining of collagen type I and type II 
For chondrogenic pellets, cryosections were pretreated with hyaluronidase (4800U/ml, 
Sigma, UK) for 2 hours and fixed in 10% formalin for 10 minutes. For sheep meniscus 
explants, wax sections were dewaxed in Histo-Clear II (NAT1328, National Diagnostic, 
USA) twice for 5 minutes and successively rehydrated in 100 % x2, 90% and 70% 
isopropanol for 2 minutes each. Sections were then washed with PBS and incubated 




Cambridge, UK) and a collagen type II antibody (1:50, clone CIIC1, DHSB, University 
of Iowa, USA) in PBS for 1 hour. Negative control sections were incubated with 
nonspecific, isotype matched antibodies (for collagen type I: IgG2a; for collagen type 
II: IgG1, Dako, Denmark) instead of primary antibodies at the same concentration. 
Sections were then washed in PBS before incubation with the secondary biotinylated 
antibody at 50 µg/mL (goat anti-mouse, VECTASTAIN ABC kit, Vector Laboratories, 
Peterborough, UK) for 30 minutes. 0.3% (v/v) hydrogen peroxide in methanol (BDH) 
was applied for 30 minutes to eliminate endogenous peroxidase activity. Labelling was 
enhanced with incubation of streptavidin-peroxidase (VECTASTAIN Elite ABC kit, 
Vector Laboratories, Peterborough, UK) for 30 minutes according to the 
manufacturer’s instructions. After washing with PBS, sections were visualised with 
diaminobenzidine (DAB, ImmPACT, Vector Laboratories, Peterborough, UK). Then 
sections were dehydrated as described above before mounting under glass coverslips 
with Pertex mounting medium. The immunohistochemistry staining intensity of 
collagen type I and type II was quantified using ImageJ Fiji Software (version 1.2; WS 
Rasband, National Institute of Health, Bethesda, MD) 165. 
2.8.6 Histological grading of human meniscus tissue 
All meniscus samples were categorised using the macroscopic meniscus grading system 
(Figure 2.6 & Table 2.4) and microscopic meniscus grading system (Table 2.5) 29.  For 
both scoring systems, a higher number represents the most degeneration, with 0 being 
totally normal. The total score from the histological assessment can be converted to a 
grade system: Grade 1 represents normal tissue with scores ranging from 0 to 4. Grade 
2 indicates mild degeneration with scores ranging from 5-9. Moderate degeneration is 
seen in Grade 3 tissue (scores of 10-14), while Grade 4 represents the most severe 




appeared in Grades 3-4.  
 
Figure 2.6:  Macroscopic meniscus assessment 
(A) Grade 1; (B) Grade 2; (C) Grade 3: partial substance tears (right arrow); (D) 
Grade 4: full substance loss of tissue (left arrow); Red in (B)-(D) indicate the 
degeneration pattern  Reproduced from Pauli et al.29 (reprint permission from Elsevier) 
 
Table 2.4: Macroscopic meniscus scoring system 
Grade Description 
1 Normal intact menisci, attached at both ends with sharp inner borders, no 
meniscal tibia or femoral surface changes 
2 Fraying at inner borders, tibial or femoral surface fibrillation, no tears 
3 Partial substance tears, fraying, tibial or femoral side fibrillations 
4 Full/complete substance tears, loss of tissue, tissue maceration 





Table 2.5: Microscopic meniscus scoring system 







A Smooth 0 
B Slight fibrillation or slightly undulating 1 
C Moderate fibrillation or markedly undulating 2 
D Severe fibrillation or disruption 3 
Tibial 
side 
A Smooth 0 
B Slight fibrillation or slightly undulating 1 
C Moderate fibrillation or markedly undulating 2 
D Severe fibrillation or disruption 3 
Inner 
border 
A Smooth 0 
B Slight fibrillation or slightly undulating 1 
C Moderate fibrillation or markedly undulating 2 
D Severe fibrillation or disruption 3 
Cellularity 
A Normal 0 
B Diffuse hyper cellularity 1 
C Diffuse hypo/acellular regions 2 
D Hypocellularity (empty lacuna, pycnotic cells) 3 
Collagen 
organisation/alignment 
and fibre organisation 
A 
Collagen fibres organised, homogenous 
eosinophilic staining of extracellular matrix 
0 
B 
Collagen fibres organised, diffuse foci of 
hyaline or mucinous degeneration 
1 
C 
Collagen fibres unorganised, confluent foci or 




Collagen fibres unorganised, fibrocartilaginous 
separation (oedema, cyst formation), severe 





A None 0 
B Slight 1 
C Moderate 2 
D Strong 3 
Cell clusters: present +, ++, +++ Calcium deposition: present +, ++, +++; Total score converted 
to meniscal grade:  Grade 1 (normal) =0-4, Grade 2 (mild degeneration) =5-9, Grade 3 
(moderate degeneration) =10-14, Grade 4 (severe degeneration) =15-18. Reproduced from 




2.9 Fibrinogen and thrombin polymerisation 
2.9.1 Mechanism of Fibrinogen and Thrombin Blood-Clotting Cascade 
The fibrinogen molecule is a 340kDa plasma glycoprotein, which consists of two sets 
of Aα-, Bβ-, and γ- polypeptide chains linked by 29 disulphide bonds (Figure 2.8)166–
168. Bβ and γ chains together compose a D-region, which is connected with the E-nodule 
through a coiled-coil segment. The Aα chains are the longest, which extend into a high-
flexible series followed by a globular αC-terminus that is located close to the E-region 
168. Thrombin is a serine protease which is formed by proteolytically cleaved 
prothrombin (coagulation factor II) 169. Fibrin formation is initiated by thrombin-
mediated cleavage of fibrinopeptides (Fp)A and FpB from the fibrinogen. The 
polymerisation starts with cleavage of FpA into half-staggered, overlapping protofibrils. 
Subsequently, FpB is cleaved from fibrinogen and fully releases Aα-chains from the E-
region, which leads to the lateral aggregation of protofibrils into fibres yielding a fibrin 





Figure 2.8: Schematic representation of fibrin formation.  
Fibrinogen consists of two sets of Aα-, Bβ-, and γ-chains. The Aα-chains are connected 
with the E-region through fibrinopeptide A (FpA, orange) and fibrinopeptide B (FpB, 
green). The D region is composed of β-, and γ-chains and connected with the E-region 
by a coiled-coil segment. Fibrin formation initiates with cleavage of FpA by thrombin 
to polymerises into protofibrils, followed by cleavage of FpB which leads to the release 
of the α-chain C-terminal and lateral aggregation. Reproduced from Undas et al. 166 
(permission under request) 
 
2.9.2 Fibrin gel in polyurethane scaffold penetration test 
To test the feasibility of using a fibrin gel as a carrier to deliver cells into a clinically 
used synthetic meniscus scaffold, a polyurethane scaffold (Actifit®) was selected. 
Actifit® was sectioned vertically into 4 mm thick triangular pieces. Fast green solution 
was used as an indicator of fibrin gel distribution within Actifit® scaffold. It was mixed 
with 20 mg/ml fibrinogen (F8630, Sigma-Aldrich, USA) and 1500μl was injected into 




(T4648, Sigma-Aldrich, USA) was added into the scaffold in a ratio of 3:1. After 30 
minutes of polymerisation, a scaffold was sectioned horizontally in half to check if the 
fibrin gel penetrated through the entire scaffold. 
2.9.3 Chondrocyte viability in polyurethane scaffold with fibrin gel 
Human chondrocytes (P5) were thawed from our cell biobank and cultured until 80% 
confluence, at which time cells were detached using trypsin and counted. 2mm x 2mm 
core scaffolds were obtained from Actifit® scaffolds using a dermal biopsy punch 
(2.0mm, Kai Medical, Japan). The experiment was divided into three groups (with 
triplicates in each group), including (i) scaffold alone (negative control group), (ii) 
scaffold with chondrocytes group (cell group) and (iii) scaffold with chondrocytes 
delivered by fibrin gel (fibrin gel group). In the cell group, chondrocytes were 
resuspended in 100μl of media at a concentration of 2 x 105 cells/ml and loaded onto 
scaffolds (2 x 104 cells/scaffold). In the fibrin gel group, chondrocytes were 
resuspended in 75μl of fibrinogen (20mg/ml) at a concentration of 2.7 x 105 cells/ml 
and injected into scaffolds, followed by the addition of 25μl of thrombin (100U/ml) 
with 100U/ml aprotinin supplement (resulting in 2 x 104 cells/scaffold). The constructs 
were placed in 96 well plate and incubated at 37° C for 30 minutes to facilitate cellular 
attachment and polymerisation of fibrin gel. A pilot experiment was performed to 
optimise the polymerization time of chondrocytes-fibrinogen and thrombin at 15mins, 
30mins and 60mins in a colon ring. The results showed after 30mins or 60mins 
incubation, the fibrin gel could form firm column to stand on its own without colony 
ring support, whereas after 15mins incubation, the gel could not maintain its shape after 
removal of colony ring. Therefore, 30mins incubation time was chose to facilitate 
cellular viability and polymerisation of fibrin gel. Subsequently, a further 200 µl of 




After 14 days culture, cell viability in the scaffold was assessed using a LIVE/DEAD 
viability assay kit (Invitrogen, UK). The scaffolds were cut in half, washed in PBS, 
followed by incubation in 2μM calcein AM (live cells, green) and 4μM ethidium 
homodimer-1 (EthD-1, dead cells, red) in culture media. Sections were washed again 
in PBS and imaged with a Leica TCS SP5 spectral confocal microscope (Leica 
Microsystems, Milton Keynes, UK). 
2.10 Statistical analysis 
All statistical analyses were performed in GraphPad Prism (Version 8.30, San Diego, 
California, USA) or R (The R Foundation, Vienna, Austria). Different statistical tests 
used for specific experiments are introduced in the experimental design and results 
section. Shapiro-Wilk normality test was used to determine the distribution of data. 
Parametric and nonparametric tests were applied for normally and abnormally 
distributed data, respectively. Data were presented as mean ± standard deviation (SD) 




Chapter 3: Characterisation of Regional 
Meniscal Cell and Chondrocyte Phenotypes 
and Chondrogenic Differentiation in 





Several studies have indicated that degeneration of the meniscus contributes to  knee 
OA pathogenesis 171. MRI frequently indicates meniscus degeneration as a key feature 
in the osteoarthritic knee, which contributes to some of the joint space narrowing that 
is typically observed 172. Degenerative meniscus tears interfere with the conversion of 
axial loading into horizontal tensile strain which can increase articular cartilage stress 
leading to cartilage loss 173. In combination, this body of evidence indicates that 
meniscus degeneration is a key contributor in OA disease processes.  
In a previous study, degenerate meniscus histological features were described 29, these 
included the identification of cell clusters, hypercellularity (diffuse) and cellular 
hypertrophy, tears, fraying and calcification. Others have showed there to be collagen 
fibre disorganization and higher levels of proteoglycans in the matrix as indicated by 
histological and electron microscopy analyses in end-stage OA patients 174. Further, the 
degenerated meniscus was shown in another study to be altered in terms of its 
biochemistry, the extracellular matrix was disorganized and the expression and 
synthesis of ECM proteins was altered 175. The precise mechanism(s) underpinning the 
degeneration associated changes remain to be clarified. In this chapter the surface 
immunoprofile and transcription profile of degenerated meniscus have been 
characterised, which will add to the scientific literature describing meniscus cell and 
tissue alteration during the OA disease process. 
Three cell types are present within the meniscus itself 24. In the avascular zone (inner 
and middle part of the meniscus), cells with an oval or round morphology reside known 
as fibrochondrocytes 176. In the outer third of the tissue fibroblast-like cells are present 
surrounded by dense connective tissue 176. The final cell type is found in the meniscus’s 




represent a sub-population of progenitor cells 177. Meniscal cell phenotypes and 
transcription profiles have been characterised previously in non-diseased human and 
animal tissues 23,178,179. However, the comprehensive phenotypic and gene profile of 
degenerate meniscal tissue-derived cells and their immunoprofiles from the distinct 
regions of osteoarthritic menisci have not previously been described. 
Human lateral and medial menisci possess some distinct morphological features 24. The 
lateral menisci demonstrate a wider range of size and thickness variety compared to the 
medial menisci 4. Further, the lateral menisci cover a greater portion of the tibial plateau 
(59 ± 6.8% laterally) compared to the medial meniscus (50 ± 5.5% medially) 180. 
However, in this study we have investigated only cells derived from the lateral menisci 
from lateral compartment in medial OA patients at the time of TKR surgeries, mainly 
due to the lack of availability of intact medial menisci in these patients. 
Meniscus tissue engineering strategies that use cell-based therapies are thought to 
represent an exciting new tool which may one day be used by clinicians to repair or 
regenerate damaged or degenerate menisci 181. Meniscal cells have been shown to have 
cartilage matrix forming capacity in vivo and vitro104,182. However, meniscal cells 
derived from patients who have undergone debridment of bucket handle meniscal tears 
when induced chondrogenic in micromass cultures were able to produce less collagen 
type II and more collagen type I in comparison to donor-matched  MSCs 104. In addition, 
this study indicated that rabbit meniscus punch defects could be successfully repaired 
at 12 weeks by transplanting them with meniscus cell seeded hyaluronan-gelatin 
scaffolds. Further, a sheep meniscus defect study demonstrated that implantation with 
autologous meniscal cells carried using a CMI® produced enhanced repair ECM and 
vascularisation at 3 months post-op compared to unseeded scaffold controls and in 




findings from these studies suggest that implanted meniscal cells contributed to the 
improved repair, although whether or not meniscal cells derived from degenerate 
tissues can retain this ability to repair is currently unknown. 
The work described in this chapter has already been published 183 and includes the 
characterisation of meniscal cell phenotypic markers and chondrogenic capacity. It 
compares cells derived from the inner (avascular) and outer (vascular) zones also 
compared to donor-matched articular chondrocytes derived from the lateral femoral 
condyle, recovered from TKR surgeries from patients affected by medial compartment 
OA in their knee joints. The findings from this study have the aim of furthering 
knowledge regarding the OA pathology in these tissues, assessing the potential of cells 
derived from OA meniscal tissues for regenerative medicine strategies including 




3.2 Experiment design 
All the tissue samples used in this study were obtained from patients who were 
undergoing TKR for the treatment of medial compartment OA (n=10; mean age 66.4 
± 11.1; age range 46-87 years; 4 males, 6 females). Intact lateral menisci and donor-
matched articular cartilage from the lateral femoral condyle were harvested and 
processed to digest avascular and vascular meniscal cells and chondrocytes as chapter 
2.1.2 described. PDTs were calculated for each cell type (from passage 0-3) (chapter 
2.3). Prior to digestion, a meniscus cross section was embedded in paraffin for 
histological evaluation using the meniscus microscopic grading system as chapter 2.8.6 
described. Flow cytometry was used to assess three cell types of surface markers 
including MSCs markers (CD14, CD19, CD34, CD45, CD73, CD90, CD105, HLA-
DR), chondrogenic potency and cell adhesion molecules (CD29, CD39, CD44, CD49b, 
CD49c, CD151, CD166, CD271) at day 14 in passage 0 for 10 donors. At passage 2, 
prior to chondrogenic differentiation, a smaller flow panel including chondrogenic 
potency molecules (CD39, CD44, CD271) and those in which a marked difference was 
observed between cell populations at passage 0 (CD49b, CD49c, CD166) were 
investigated in 6 donors according to chapter 2.4.2. qRT-PCR was performed to assess 
the gene expression levels of collagen type I (COL1A2), collagen type II (COLIIA1), 
aggrecan (ACAN), SOX-9 and matrix metalloproteinase-1 (MMP-1) and normalised to 
the housekeeping gene GAPDH as chapter 2.7 described. The chondrogenic potency of 
the three donor-matched cell populations was assessed at passage 2 using a well-
established 3D pellet culture system in 6 donors as chapter 2.5 described. After 28 days 
in culture, n=3 pellets were used for biochemical GAG/DNA quantitation (chapter 2.6), 
n=3 pellets were snap frozen in liquid nitrogen-cooled hexane and cryosectioned for 




BDH, UK) to assess the general tissue morphology and GAGs composition of the 
extracellular matrix. In addition, immunohistochemistry for collagens type I and II was 
undertaken as chapter 2.8.5 described. The immunochemistry staining intensity of 
collagen type I and  type II was quantified using ImageJ Fiji Software (version 1.2; WS 
Rasband, National Institute of Health, Bethesda, MD) 165. 
All data were inputted into GraphPad Prism (Version 7.04, USA) and Jamovi (Version 
1.1.9.0) for statistical analysis. Differences between cell types were assessed by 
performing one-way ANOVAs with Tukey’s multiple comparisons for population 
doubling time, positive percentage fluorescence signal, gene expression level, 
GAG/DNA comparisons and semi-quantitative of collagen type II IHC intensity. Two-
way ANOVAs were used to compare the positive percentage fluorescence signal of 
different cell types and histological scores in avascular and vascular regions. The 
Jonckheere–Terpstra test was used to assess the correlation between the positivity of 
surface markers and meniscus histological scores. Multilevel modelling was performed 
to determine whether expressions of cell surface markers were associated with 
chondrogenic outcome as measured by GAG/DNA content. Cell source and cell surface 
marker positivity were considered as fixed effects, while the donor was considered as a 
random effect. Our lab previous data from flow marker reliability test (not published) 
was used to evaluate the reliability of chondrogenic predictors in multilevel modelling 







3.3.1 Histological scoring and analysis of meniscus sections 
Ten patients (6 males and 4 females, ages 46-87 years) who were undergoing TKR 
(Table 3.1) provided donor-matched samples of meniscus and cartilage tissues. 
Avascular and vascular zones were noted to frequently present with differing states of 
degeneration and hence, were graded separately using histological analyses. The 
intensity of matrix metachromatic staining in the vascular zone was found to be 
significantly elevated compared to the avascular zone of the tissue (Figure 3.1). In 
addition, the inner zone of the avascular region was shown to score 2 or 3. This data 
could indicate that the inner region of the meniscus tissue is the first to be affected in 
the OA disease process. No significant differences were seen when comparing 
avascular and vascular regions in terms of the other histological parameters measured.  
Table 3.1: Demographics of donors from which samples were sourced. 
ID Gender Age Meniscus Microscopic grading 
Donor 1 Male 46 Lateral 2 
Donor 2 Female 53 Lateral 4 
Donor 3 Female 66 Lateral 3 
Donor 4 Female 66 Lateral 2 
Donor 5 Male 66 Lateral 2 
Donor 6 Female 67 Lateral 2 
Donor 7 Male 69 Lateral 3 
Donor 8 Male 69 Lateral 3 
Donor 9 Female 75 Lateral 2 





Figure 3.1: Histological grading results of avascular and vascular regions of the 
meniscus. 
Avascular (solid bars) and vascular (hashed bars) regions were scored histologically 
and compared in terms of significance. The GAGs staining intensity in the vascular 
region was significantly higher than in the avascular region; (Grade 1: 0-3; Grade 2: 
4-7; Grade 3: 8-11; Grade 4: 12-15). The grading criteria was presented in chapter 
2.8.6 
 
The histological analyses undertaken revealed several noteworthy observations. Along 
the inner border fibrillation was apparent with disrupted tissue structures and/or 
abnormal cellularity observed throughout. These changes seemed to go hand in hand 
with oedematous matrix changes close to surface (Figure 3.2a). Chondrocyte-like cells 
were visualised in the swollen oedematous region as well as frequent cell clusters 
surrounded by an acellular ECM. Further, toluidine blue (TB) staining intensity was 





Figure 3.2: Representative avascular region meniscus histology from donor 9 stained 
with H&E and TB (Grade 2) 
(a) Oedematous changes were observed in the meniscus surface zone, where the cells 
often appeared chondrocytic (*) sometimes forming clusters (dashed line). The area 
surrounding the oedematous region was typically acellular (▲) Note the necrotic 
appearance of some cells in this area and within the clusters (↗); (b) A higher intensity 





A bundle of transverse collagen fibres, known as the transverse ligament, were found 
transcending from the synovial edge (Figure 3.3a) into the vascular region. In all of the 
10 patient samples analysed a “tree-like” formation of fibres was observed in the 
avascular region (Figure 3.3b), which under polarized light was clearly visible (Figure 
3.3c). The ligament structure was closely associated with blood vessels in all six of the 
Grade 2 menisci studied (Figure 3.3d). In the Grade 3 and 4 menisci, however, fewer 







Figure 3.3: Representative images of Grade 2 (b-d: donor 4) and Grade 3 (e, f: donor 
9) menisci with H&E staining 
(a) Cross-sectional illustration of the meniscus. “Tree-like” transverse collagen fibres 
(yellow) run into the vascular region radially from the synovial tissue. (b) The “tree-
like” structure is indicated with a dotted line; (c) Again, the “tree-like” structure 
(dotted line) is indicated and visualised using polarized light; (d) Along the “tree” root, 
blood vessels (arrows) were seen; (e) In the Grade 3 menisci the matrix was fragmented; 
(f): The “tree-like” structure was without blood vessels and more degenerate in the 




3.3.2 Growth kinetics  
Vascular meniscal cells proliferated significantly faster at passage 0-1 compared to 
avascular meniscal cells (p=0.0191) and chondrocytes (p=0,0057) (Figure 3.4). Cell 
PDT decreased as the passage number increased across all cell fractions. However, this 
observation should be considered a trend, as no significant differences were observed 
between passages. 
 
Figure 3.4: Population doubling time (PDT). 
Graph depicts the PDT of donor-matched fractions of avascular and vascular meniscal 
cells as well as chondrocytes (passage 0-3). 
 
3.3.3 Cell surface markers analysis 
At passage 0, for all fractions and for all 10 donors, immunopositivity for CD73, CD90, 
CD105 >95%, adhering to ISCT criteria 152; However, ~25% of cells were  
immunopositive for CD14, which according to the ISCT criteria, should be <2%, but is 
similar to levels previously reported in MSCs derived from other musculoskeletal 




was >95% on avascular and vascular meniscal cells and >90% on chondrocytes. 
Whereas CD19 (B lymphocyte antigen), CD34 (haematopoietic progenitor cell antigen), 
CD45 (protein tyrosine phosphatase receptor type C), CD271 (low-affinity nerve 
growth factor receptor) and HLA-DR (human leukocyte antigen-DR) were all <5%, no 
significant difference was observed between groups. However, CD49b (integrin α2), 
CD49c (integrin α3) and CD166 (activated leukocyte cell adhesion molecule) displayed 
significantly different immunopositivity across the three fractions (two-way ANOVA) 
(Figure 3.5a). At passage 2, similar patterns were observed across the 6 donors tested 
pre-chondrogenic differentiation, with significant differences between CD49b and 
CD49c, but not CD166 indicated (Figure 3.5b). Avascular cells showed the highest 
level of immunopositivity for CD49b at passage 0 (53.89 ± 17.41%), which was lowest 
on chondrocytes (16.80 ± 7.03%) with 41.46 ± 14.95% of vascular cells being 
immunopositive. The levels of positivity for CD49b on the three cell fractions followed 
a similar pattern (avascular: 81.47 ± 11.88%, vascular: 73.03 ± 11.36%, chondrocyte: 
47.16 ± 21.81%), although no significant differences were observed. Immunopositivity 
for CD49c was 73.30 ± 19.84% on avascular meniscal cells, which was significantly 
higher than vascular meniscal cells (60.47 ± 32.99%) and chondrocytes (53.69 ± 
30.60%) at passage 0. Immunopositivity for CD49c on avascular meniscal cells was 
significantly higher than for the other cell populations, but those from the vascular 
region were significantly lower than chondrocytes (avascular: 79.99 ± 14.91%, vascular: 
54.70 ± 23.04%, chondrocyte: 68.19 ± 13.46%). Further, immunopositivity for CD166 
at passage 0 was significantly higher on avascular (83.47 ± 14.41%) and vascular (81.68 
± 16.95%) meniscal cells compared to donor matched chondrocytes (53.47 ± 21.09%). 
Interestingly, the length of time spent in culture appeared to upregulate CD166 on 




significant differences across the different cell fractions at passage 3 (avascular: 97.50 
± 3.26%, vascular: 95.50 ± 3.22%, chondrocyte: 89.82 ± 7.97%). 
 
 
Figure 3.5: Flow cytometry outcomes 
(a) All of the donor matched fractions tested showed comparable patterns of 
immunopositivity for the markers investigated at passage 0. Immunopositivity for 
CD49b, CD49c and CD166 was greater on meniscal cells compared with chondrocytes 
(10 donors); (b) CD49b and CD49c immunopositivity showed similar trends across the 




3.3.4 Comparing flow profiles and histological analyses 
Histological parameters scored in the avascular and vascular regions were significantly 
related to the immunopositivity of the six markers tested in the study (Table 5.2). 
Jonckheere-Terpstra testing revealed that when the meniscus tibial surface was more 
severely disrupted in the avascular region, the median number of avascular meniscal 
cells which were immunopositive for CD49b (p = 0.009) and HLA-DR (p = 0.028) 
increased. In addition, when the inner border had more severe disruption in the meniscal 
tissue, positivity for CD49b was higher in avascular meniscal cells (p = 0.018); the 
same relationship was shown for CD29 (p = 0.047). Interestingly, when increased 
hypocellularity was observed in the vascular zone, the median immunopositivity for 
CD34 and CD39 in vascular meniscal cells increased (p = 0.005 and p = 0.049, resp.). 
Further, in the vascular zone, GAGs intensity increased and more of the vascular 




Table 3.2: Correlation between surface markers and histology scores 
Jonckheere-Terpstra test: Avascular region (grey shading); vascular region (white 
shading). The significant values are highlighted in bold and italics. The full table 
content in appendix III 
3.3.5 Gene expression profiles: Donor-matched analyses of avascular and vascular 
meniscal cells and chondrocytes 
SOX-9 expression was significantly higher in chondrocytes compared to avascular and 
vascular meniscal cells (Figure 3.6a). Unsurprisingly, collagen type I expression was 
significantly higher on the avascular and vascular groups compared to donor matched 
 
Region 
Tibial Inner border Cellularity GAG intensity 
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CD19 
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Vas 0.492 0.688 0.218 - - - 0.756 0.311 0.098 0.024 2.261 0.715 
CD29 
Avas 

































Vas 0.280 1.080 0.342 - - - 0.005 2.800 0.885 0.100 1.644 0.520 
CD39 
Avas 










Vas 0.202 1.277 0.404 - - - 0.049 1.970 0.623 0.681 0.411 0.130 
CD49b 
Avas 



























chondrocytes (Figure 3.6b).  No significant differences were found across the cell 
fractions in the expression levels of collagen type II (COL II), aggrecan (ACAN) or 
MMP-1 Figure 3.6c-e). 
 
Figure 3.6: qRT-PCR outcomes 
The MMP1 and chondrogenic gene expression profiles in Avas, Vas and Chondrocytes 
after 14 days in monolayer culture (a-e). Data shown are the means ± SD of n=3 
technical replicates and n=10 donors for each cell fraction.  Gene expression is shown 




3.3.6 In vitro chondrogenic pellet analysis 
At 28 days post-chondrogenic differentiation GAG/DNA analyses revealed that 
chondrocytes consistently produced the highest levels of GAGs, avascular meniscal 
cells also showed lower GAGs levels compared to vascular meniscal cells (Figure 3.7a). 
The histological grading of TB intensity in the avascular and vascular zones appeared 
to match this data, in that, the vascular regions demonstrated more pronounced matrix 
metachromasia compared to avascular regions (Figure 3.1a; Figure 3.7a). 
Chondrogenic capacity across individual donors was variable. In general, collagen type 
I staining was observed in all pellets and across cell types after 28 days of chondrogenic 
induction. The highest staining intensity for collagen type I was seen in the vascular 
meniscal cell fraction (Figure 3.7b & c), collagen type I gene expression profiles 
seemed to mirror this pattern for each cell population (Figure 3.6b). In contrast, weak 
collagen type II staining were detected in all cell fractions, although significantly 
stronger staining intensity was observed in chondrocyte pellets compared to vascular 





Figure 3.7: The chondrogenic assessment of avascular and vascular meniscal cells 
and chondrocytes. 
(a) A comparison of Avascular (Avas) and Vascular (Vas) meniscal cells and 
chondrocytes (Ch) in terms of GAG/DNA quantitation after 28 days of culture in pellets. 
Data shown are the means ± SD of n=3 runs and n=6 donors for each cell fraction. (b) 
Representative donor 6 histological analysis of pellet sections from Avas, Vas, Ch 
showing toluidine blue (TB), collagen type I (COL I) and collagen type II (COL II) 
staining. Scale bars represent 250𝜇m. (c) Collagen type I and (d) collagen type II semi-





3.3.7 Chondrogenic potency analysis 
Statistical multilevel modelling was conducted in order to identify chondrogenic 
potency indicators pre-chondrogenic differentiation (Table 3.3). CD49b positivity was 
shown to be associated with GAGs levels (p = 0.035). Similar to previous chondrogenic 
analysis (Figure 3.7a), cell types (vascular meniscal cells and chondrocytes) had a 
significant impact on GAGs quantitation compare to avascular meniscal cells (p = 0.003 
and p < 0.001, respectively). CD44 expression was also shown to be negatively 
associated with GAGs quantitation in pellets (p = 0.011). 
Table 3.3: Multilevel modelling 
 95% Confidence Interval  
 Coefficient Lower Upper p 
CD34 -0.4543 -1.8915 0.983 0.553 
CD39 0.277 -0.0109 0.565 0.096 
CD44 -77.5159 -123.7309 -31.301 0.011 
CD49b 0.4098 0.0922 0.727 0.035 
CD49c 0.0606 -0.1577 0.279 0.601 
CD166 -0.2386 -0.6014 0.124 0.233 
CD271 -2.911 -6.1629 0.341 0.117 
Vascular-Avascular 21.0973 11.0721 31.122 0.003 
Chondrocytes-Avascular 44.3104 29.7228 58.898 < .001 







It is generally accepted that meniscus degeneration can cause the breakdown of articular 
cartilage in the knee and the early onset of OA 24. However, the exact mechanisms of 
early meniscus degeneration are unclear, especially with regards to the cellular 
phenotypic changes and ECM alterations 185. This study undertook an extensive 
characterisation of avascular and vascular meniscal cells derived from the lateral 
menisci from TKR surgeries. Although we carefully chose regions with an integral 
morphology, these tissues were certainly influenced by an OA pathological condition 
for an extended period. In the medial compartment of OA patients, the greater medial 
loading disturbs the normal mediolateral load distribution balance. This mismatched 
balance results in lateral compartment lift-off 186. Consequently, the lateral meniscus 
undergoes extraordinary decreased loading which decelerates its tissue degeneration 187. 
Our histological findings showed that the lateral menisci obtained from such joints have 
suffered in various degrees of deterioration as was revealed by our use of  an established 
meniscal histological grading system 29. 
Petersen et al. 15 reported on the loosely arranged collagen fibres which developed from 
the joint capsule and inserted horizontally between the circular collagen fibres of the 
meniscus. The meniscus sample used in this study has identified these “tree-like” 
shaped structures in all donors. However, to the best of our knowledge, no previous 
study has outlined how/if these “tree-like” collagen fibres are involved with the 
pathological development of knee OA. Arnoczky et al. 9 showed there to be radial 
division of blood vessels originating  from the perimeniscal capillary plexus, 
penetrating the meniscal matrix shortly into the main body of the meniscus, which 
seemed to associate with the “tree-like” collagen fibres penetrating into the meniscus. 




“root” of the collagen fibre “tree”. However, the vessels were only discovered in the 
“root” in the Grade 2 menisci and were rarely present in the same area in Grade 3 or 4 
samples. This result matches up with previous research, which noted blood vessel 
occurrence only in the dense connective tissue but not in the fibrocartilage 30. The same 
study also reported that only 25% of the outer meniscus was vascularised in the aged 
menisci, whereas the outer one third of the meniscus was vascularised in young adult 
menisci. Degenerative meniscal tears mostly have a complex pattern, which are 
generally found in the mid to posterior of the meniscus 185. APM or non-operational 
treatment is normally selected to handle these patients because of the poor healing 
ability of the degenerative meniscus 54. The declined blood supply observed in the 
vascular zone of the degenerate meniscus may play a major role in the decreased self-
healing capacity noted in this region. 
The meniscal cells from the OA joint composed of a diverse population, which has not 
been well characterised previously. In our study, commonalities found in the surface 
molecules (CD14, CD19, CD29, CD34, CD39, CD44, CD45, CD73, CD90, CD105, 
CD151, CD271, HLA-DR) on avascular and vascular meniscal cells and chondrocytes 
imply that they possess similar characteristics and perhaps also chondrogenic potency, 
as many of these markers have been suggested to be predictive of in vitro chondrogenic 
capacity. Despite these similarities, distinctions in CD49b (integrin α2), CD49c 
(integrin α3) and CD166 (ALCAM) were noticed between meniscal cells and 
chondrocytes derived from OA joints. Grogan et al. 178 reported, in the normal human 
meniscus, a higher percentage of meniscal cells that were positive for CD14 (LPS-
receptor), CD26 (dipeptidyl peptidase IV) and CD49c in contrast to chondrocytes 
(n=10). The differences found in our study in comparison may indicate that the OA 




Grogan et al.178 highlighted that immunostaining of CD166 was positive on cells that 
predominately surrounding the blood vessels in the vascular region of the meniscus and 
on cells at the meniscus surface, which could suggest the presence of progenitors in 
these regions, as CD166 has previously been used to recognise chondroprogenitors in 
healthy cartilage 188. A previous study demonstrated that freshly isolated vascular 
meniscal cells expressed higher positivity of CD34 (stem cell marker) and CD146 
(pericyte marker) compared with avascular meniscal cells in the lateral meniscus from 
knee OA patients. These CD34 and CD146 positive meniscal cells displayed 
multilineage differentiation capabilities, which also favoured meniscus repair in a rat 
model 189. Our flow cytometry analysis showed greater expression levels of CD166 in 
the vascular meniscal cells compared to avascular cells. In addition, the cell growth 
kinetics analysis showed that the vascular meniscal cell fraction proliferated faster than 
the other donor-matched cell types. These findings indicate the existence of progenitors 
associated with the blood vessels or perhaps that the vasculature in the outer zone of 
the meniscus drives a more progenitor-like phenotype. This is further supported by our 
theory that the “tree-like” fibres which connects the joint capsule and meniscus together, 
not only provide the structural support and blood supply to the outer region, but may 
also contains a conduit for the “progenitors” which may arise from synovium, as CD166 
positive progenitor populations have been noted in the synovium tissue of OA knees 
190. Ideally, in future work aimed at confirming these hypothesise cell sorting could be 
used to isolate and analyse CD166 positive populations for progenitor phenotypic 
characterisation. In the more degenerate meniscus, we noted the shortage of blood 
vessels in “tree-like” fibres, which may indicate that this structure (consisting of 
collagen fibres, blood vessels and cells) plays a key role in preventing the meniscus 




investigation before definite conclusions can be drawn. In addition, the progenitor 
population in the “tree root” may have regenerative features relevant to the 
improvement of meniscus tissue engineering strategies.  
Integrins play an important role in the interactions between chondrocytes and the ECM 
in the OA pathological process of cartilage degeneration 191. However, the role that 
integrins have in the deterioration of the meniscus is still uncertain. CD49b and CD49c 
are integrin-α subunits which were categorized as ECM receptors for collagens, 
laminins and fibronectin 158. CD49b expression was reportedly increased in the 
cartilage of a mouse model after OA induced 45 days compare to normal cartilage 192. 
The same study also reported that cell signalling through CD49b was induced by 
changes in the ECM, which activates the catabolic pathway of chondrocytes and 
favoured cell apoptosis as a result of elevated MMP activity. Integrin α3 was also found 
to be abnormally expressed in the knee of a destabilised medial meniscus (DMM) 
mouse model, which was closely linked with the onset of OA 193. Our flow cytometry 
results demonstrated that the expression levels of CD49b and CD49c were greater in 
avascular meniscal cells compared with vascular meniscal cells and chondrocytes at 
both P0 and P2. This might be because the fraying of the avascular rim was found in 
OA samples in this study, perhaps indicating a more progressive response to OA 
development in the avascular region of the meniscus compared to the other regions. The 
correlation results also demonstrated that with more disrupted tissue structures in the 
meniscal inner rim, the immunopositivity for CD49b and CD29 (integrin β1) in the 
avascular meniscal cells significantly increased. Integrin β1-collagen interaction is a 
crucial signalling pathway for chondrocyte survival, which  prevents chondrocytes 
apoptosis 194. Therefore, our results could support the hypothesis that the OA-like ECM 




CD49c and CD29, although additional mechanistic study will be required to draw firm 
conclusions. 
The multilevel modelling analysis carried out to find indicators of chondrogenic 
potency in this study indicated that greater expression levels of CD49b were 
significantly associated with higher GAGs production. A previous study showed that 
gene expression level of CD49b was up-regulated in 3D pellets of human chondrocyte 
at day 14 compared to monolayer cultures 195. Another study demonstrated that GAGs 
quantities were significantly higher in pellet cultures of BM-MSCs compared to 
monolayer cultures 196. However, the expression level of CD49b in pre-pellet formation 
has not previously been proved to correlate with higher post-pellet GAG productions.  
Several limitations need to be noted in this study. Firstly, we have focused entirely on 
the lateral meniscus from the medial compartment of an OA knee. Including the medial 
menisci from the lateral compartment of osteoarthritic knees would make for a more 
comprehensive study. However, inadequate samples for this comparison could be 
achieved because knee OA is less commonly seen in lateral rather than the medial 
compartment 197. Another limitation of this study is that the gene expression levels were 
not checked in chondrogenic pellets but only in monolayer cultures because of limited 
cell numbers. Such chondrogenic related gene expression analysis would complete the 
chondrogenic potency analysis conducted in the study.  
In conclusion, our study suggests that CD49b, CD49c and CD166 are phenotypic 
markers which could differentiate cells from avascular or vascular meniscus and 
cartilage in the OA joint. We observed distinct regional meniscal cell profiles, which 
relate to histological tissue construct changes. The meniscus “tree-like” collagen fibres 
noted in the histological analysis in this study may play a key role in supporting the 




protecting against matrix degeneration. We also showed that meniscal cells derived 
from the lateral meniscus of knees with medial compartment knee OA have 
chondrogenic capacity in vitro which could be considered as a potential cell source for 




Chapter 4: Phenotypic characterisation of 





Menisci play a key role in joint congruence, dispersing load and protecting the articular 
cartilages surface of the femur and tibia 2. Although treatment of meniscus tears has 
developed dramatically including meniscus repair and replacement strategies, these 
surgical interventions’ provide limited protection against the progression of 
osteoarthritis 198,199. Therefore, there is a demand to develop other treatment to improve 
meniscus repair. 
Mobilization and homing endogenous progenitor cells from the vascular zone of 
meniscus may be responsible for some of the natural healing noted in the meniscus 
following injury 200. The meniscus is composed of an outer “vascularised” zone that 
containing fibroblast-like cells and an inner “avascularised” zone that containing round 
fibrochondrocytes. It has been long known that the vascular region tears of the meniscus 
tend to successfully repair themselves after surgical procedure, whereas the inner 
avascular region has a low healing potential 201. The better regeneration of the vascular 
part of the meniscus might be due to the presence of CD34 and CD166 immunopositive 
progenitor cells in the blood vessels in this region 189. Recent studies suggested the 
presence of progenitor cells in the meniscus that promote meniscus injury repair in 
bovine, rabbit and mouse models 202–204. In chapter three it was demonstrated that there 
were fewer blood vessels carried by “tree-like” collagen fibres in the vascular zone of 
more degenerative menisci compare with healthier ones 183. These results suggest that 
there is a subpopulation of progenitor-like cells in the vascular region. However, there 
is a lack of studies that decisively identified progenitor cell populations in human 
meniscus tissue. 
Fibronectin-coated flasks have been previously used to extract chondroprogenitors 




terms of cartilage regeneration 148. Chondroprogenitors are an ideal candidate for cell-
based tissue engineering cartilage repair strategies. Human meniscus cells and 
chondrocytes share similar cell surface markers profiles 183. In this study, the 
chondroprogenitors isolation protocol this is established in the literature 148 was used to 
obtain and characterise the progenitors and whole mixed population from donor-
matched avascular and vascular regions of the meniscus, as well as cartilage derived 
chondroprogenitors. 
4.2 Experiment Design 
Human meniscus (five patients) and cartilage tissues (four patients) were harvested 
from four patients undergoing TKR and one patient undergoing above-knee amputation 





Table 4.1. Patient Demographics. 
Patient Age Sex Procedure Tissue 
obtained 
Additional Clinical Notes 
1 37 male TKR Lateral 
meniscus; 
cartilage 
Previous HTO, medial 
artificial meniscus and 
meniscus allograft transplant, 
multiple knee wash out, 
removal of osteophyte 
2 73 male TKR Lateral 
meniscus 
Advanced OA with bone-on 
bone in medial compartment 
3 60 female TKR Lateral 
meniscus; 
cartilage 
Indication of OA from MRI 
imaging assessments 




compartment OA, significant 
osteophytes 
5 59 female AKA Lateral 
meniscus; 
cartilage 
Previous traffic accident, 
osteoporosis due to lack of use 
TKR: total knee replacement; AKA: above knee amputation; OA: osteoarthritis；HTO: 





Figure 4.1: Flow Diagram of the Experimental Plan 
Avas: Avascular meniscal cells, Vas: Vascular meniscal cells, C: Chondrocytes, TKR: 




The meniscus was dissected longitudinally into three parts: the inner avascular zone, 
the middle and the outer vascular zone. The middle portion was discarded and only the 
inner and outer avascular and vascular zones were used to derive meniscal cells. 
Additionally, full-depth macroscopically normal human articular cartilage from 
femoral condyles was used to isolate chondrocytes and their progenitors. Samples were 
digested by sequential pronase (70U/ml, 1 hour at 37℃) and collagenase type II 
(245U/ml, 12 hours at 37℃). All three cell types (avascular & vascular meniscal cells 
and chondrocytes) were cultured under two conditions. The first group was mixed 
population cells including avascular meniscal mixed cells (MAvas), vascular meniscal 
mixed cells (MVas) and mixed chondrocytes (MChs), which were plated at a density 
of 5000 cells/cm2. The second group was progenitor cells including avascular meniscal 
progenitors (PAvas), vascular meniscal progenitors (PVas) and chondroprogenitors 
(PChs), which were subjected to a selective fibronectin adhesion assay as previously 
described in chapter 2.2.1.  
After three days of culture in a 6 well plates, progenitor cells from 5 donors were 
analysed using the Cell-IQ® live cell imager for 48 hours as previously described in 
chapter 2.2.2. The recorded images were analysed using Cell-IQ® analyser software 
(CM Technologies, Tampere, Finland) in order to count the cell number in each colony 
at each time point. The number of colonies in each well were also counted under light 
microscopy post-Cell-IQ® analysis (only colonies with over 32 cells were included), 
the number of colonies counted was considered to be the initial number of progenitors 
that had adhered to the plate. Each type of polyclonal progenitor population was then 
trypsinised and cultured in complete medium with TGF-β1 (PeproTech, London, UK) 
(1ng/ml), FGF-2 (PeproTech, London, UK) (5ng/ml). 




time of cell seeding, t2 = the time of cell harvest and n = the cell population at the 
matching time points. PDTs at passages 0 to 2 and passage 2 to 3 were compared 
between mixed populations and progenitor cells, as progenitors could not be counted 
with sufficient accuracy at P0-1. 
Prior to chondrogenic differentiation, flow cytometry analysis was performed on 
avascular meniscal cells, vascular meniscal cells and chondrocytes from both mixed 
and progenitor populations as described in chapter 2.4.2. Immunopositivity for 6 
molecules which are indicative of MSCs profile (CD14, CD73, CD90, CD105), 
chondrogenic potency or cell adhesion molecules (CD44, CD49b, CD49c, CD166) 
were evaluated in all five donors. 
The chondrogenic potency of the three donor-matched populations in both mixed 
population and progenitor groups were assessed in all five donors (patient 2 only had 
matched avascular and vascular meniscal cells). After 28 days in culture, n=3 pellets 
were used for biochemical GAG/DNA quantitation (chapter 2.6) and n=3 pellets were 
used for gene expression analysis (COL2A1, COL1A2, ACAN, SOX 9, COL10A1) 
(chapter 2.7). Gene expression levels were calculated in progenitor cell pellets as a ratio 
compared to donor matched mixed population pellets, using the comparative threshold 
method. A 2-fold up- or downregulated change was considered biologically significant. 
In addition, n=3 pellets were snap frozen in liquid nitrogen-cooled hexane and used for 
immunochemistry stained with collagens type I and II. 
GraphPad Prism (Version 8.30, San Diego, California, USA) was used for statistical 
analysis. Two-way ANOVA analysis with a multiple comparisons test was used to 
analyse flow cytometry, population doubling time, RNA gene analysis, GAG/DNA 





4.3.1 Growth Kinetics and Cell Morphology in Mixed Population and Progenitor 
cells 
Figure 4.2 shows the representative mixed population and progenitor cell morphologies. 
At passage 0 (Figure 4.2A), mixed population cells were distributed randomly on tissue 
culture plastic, whereas progenitor cells were organised into round tightly packed 
colonies. PAvas and PChs had a similar oval chondrocyte-like morphology whereas 
PVas were fibroblastic spindle-shaped cells. At passage 2 (Figure 4.2B), the majority 
of the mixed population cells possessed extensive cytoplasmic processes of varying 
length 205. However, this was much less observed in progenitor cells. 
Mixed population cells demonstrated a slower growth rate in monolayer culture 
compare to progenitor cells from both passage 0 to 2 and passage 2 to 3. The mean PDT 
of MAvas, MVas and MChs at P0-2 were 15.46 ± 13.05 days, 35.40 ± 36.62 days and 
9.47 ± 3.21 days compare with 1.27 ±0.14 days, 1.25 ± 0.11 days and 1.33 ± 0.20 days 
for PAvas, PVas and PChs. A smaller difference in PDT between mixed and progenitor 
cells was seen at P2-3 with MAvas, MVas and MChs having a PDT of 15.45 ±13.16 
days, 7.18 ± 3.20 days, 9.39 ± 1.16 days and 2.91 ± 0.66 days, 3.25 ± 0.57 days and 
3.19 ± 0.77 days for PAvas, PVas and PChs. However, the only statistically significant 
difference was found between MVas and PVas at P0-2 (P=0.011) (n=5 for MAvas, 






Figure 4.2: Comparison of progenitor cells morphology on monolayer culture. 
Representative images from mixed population and progenitor cells at passage 0 (A) 
and passage 2 (B) in avascular and vascular meniscal cells and chondrocytes. Scale 






Figure 4.3: Population doubling time (PDT) of progenitor cells 
MAvas: mixed avascular meniscal cells, MVas: mixed vascular meniscal cells, MChs: 
mixed chondrocytes. PAvas: progenitor avascular meniscal cells, PVas: progenitor 
vascular meniscal cells, PChs: progenitor chondrocytes 
 
4.3.2 Cell-IQ® Analysis 
Four of five patients’ progenitor colonies of PAvas, PVas and PChs were kept under 
monitoring for 48 hours in the Cell-IQ® live cell imager. For each progenitor cell type 
from each patient, two or three colonies were selected for colonies proliferation rate 
analysis. Figure 4.4 showed the results of individual colony proliferation data. The cell 
numbers of colonies below 32 cells or doubled after 48 hours in culture was not 
considered as progenitor colonies. Three of 12 colonies for PAvas, 4 of 11 colonies for 
PVas, 4 of 10 colonies for PChs were characterised as non-progenitor colonies. After 
excluding non-progenitor colonies (11 of 33 colonies, 33.3%), proliferation data from 
progenitor colonies only was compared for PAvas, PVas, PChs fractions (Figure 4.5). 




significantly faster than PAvas (P=0.0022) and PChs (P<0.0001), whilst the PChs 
colony proliferation rate was significantly slower than the PAvas colonies (P=0.0026). 
 
Figure 4.4: Diagram of individual colony proliferation rates over 48 hours in the 
Cell-IQ®.  
Progenitor colonies (cell numbers beyond 32) were highlighted in bold line. The dashed 
line represents the threshold of minimum cell number as a progenitor colony (n=32). 
PAvas: progenitor avascular meniscal cells, PVas: progenitor vascular meniscal cells, 





Figure 4.5: The overall comparison of proliferation rate for avascular, vascular 
meniscal progenitors and chondroprogenitors.  
 
Table 4.2: Tukey's multiple comparisons test 
 Predict means, 95% CI P Value 
PAvas vs. PVas (67.00, 92.98), (-43.83 to -8.127) 0.0022 
PAvas vs. PChs (67.00, 39.53), (8.298 to 46.65) 0.0026 
PVas vs. PChs (92.98, 39.53), (32.45 to 74.45) <0.0001 
PAvas: progenitor avascular meniscal cells, PVas: progenitor vascular meniscal cells, 
PChs: progenitor chondrocytes 
4.3.3 Cell Surface Markers 
Flow cytometry analyses (Figure 4.6) revealed that all cell populations were over 95% 
positive for the ISCT MSC markers CD73, CD90 and CD105, as well as other markers 
(CD29 and CD44). CD14 was present on all cell populations, ranging an average from 
5.18% to 10.75% positivity. There was no significant difference noted for any of the 
cell markers examined between mixed population and progenitor cells. However, 




chondrogenic potency marker CD166 were noted. Progenitor cells showed significantly 
higher positivity for CD49b compared to their counterpart mixed avascular meniscal 
fractions (P<0.0001), vascular meniscal cells (P<0.0001) and chondrocytes (P<0.0001). 
Interestingly, both MAvas and PAvas had significant greater positivity for CD49b 
compare to MVas (P=0.0002) and PVas (P=0.0035), respectively. Progenitor cells also 
showed a significantly increased level of CD49c when compared to their paired mixed 
populations in avascular meniscal (P=0.0387), vascular meniscal (P<0.0001) and 
chondrocyte fractions (P=0.0035). MAvas also showed significantly higher positivity 
for CD49c compared to MVas, whereas no difference was noted in progenitor cell types. 
For CD166, MChs had a significantly lower positivity compare to MAvas (P=0.0012), 
MVas (P=0.0144) and PChs (P=0.0019). 
 
Figure 4.6: Progenitors flow cytometry outcomes 
Graphs showing the % immunopositivity of cell surface markers for donor matched 
mixed or progenitor avascular and vascular meniscal cells and chondrocytes at 
passage 2-3.  
 
4.3.4 Chondrogenic Gene Expression in Cell Pellets 




progenitor cells compared to their mixed population counterparts after 28 days in 
culture. RT-qPCR analysis of SOX9 was found to be downregulated in PAvas, PVas 
and PChs in all five patients compared with mixed population cells, apart from PVas in 
patient 5. ACAN was significantly downregulated in PAvas from patients 1, 4, 5 and in 
PChs from patient 3, 4, 5.  Expression of COL1A2 was significantly upregulated in 
PChs from patient 1 and 5 but downregulated in PVas from patient 4 relative to the 
mixed population cells. COL2A1 in PVas was significantly downregulated in patient 1 
(mean fold change 50 ± 41), patient 4 (mean fold change 5288 ± 3166) and upregulated 
in patient 2 (mean fold change 7 ± 2) and patient 3 (mean fold change 14 ± 10) compared 
with PVas. Both PAvas and PChs were significantly downregulated in patient 3-5 
compare with MAvas and MChs. Expression of COL10A1 was found to be 
downregulated in all three progenitor populations from all five patients relative to their 






Figure 4.7: RT-qPCR outcomes of progenitor cells.  
Graphs showed the genes associated with chondrogenic potency and hypertrophy from 
3D pellet culture in mixed or progenitor avascular and vascular meniscal cells and 
chondrocytes. Gene expression for mixed and progenitor group were normalized to the 
reference gene GAPDH. Data for progenitor cells are expressed relative to mixed 




4.3.5 In Vitro Chondrogenic Differentiation Analysis 
GAG/DNA analysis (Figure 4.8) demonstrated that progenitor cells generally produced 
more GAGs than mixed population cells in all three cell types, with significant 
differences noted only between MVas and PVas (P=0.027). Both MChs and PChs had 
highest GAGs production across all cell fractions. Progenitor cells formed firmer 
chondrogenic pellets in terms of their morphology compared with mixed population 
cells across all three cell types (Figure 4.9). A stronger collagen type I staining trend 
was observed in all progenitor populations compared with mixed populations without 
significant difference (Figure 4.10A). A trend for weaker collagen type II staining was 
detected in all progenitor pellets compared with mixed population pellets (Figure 
4.10B), while only MChs pellets were found to be significantly stronger for collagen 
type II staining compared to PChs pellets (P=0.0268). 
 
Figure 4.8: GAG/DNA quantitation after 28 days of 3D pellet culture 
a comparison of mixed population (mixed) and progenitor (pro) avascular and vascular 
meniscal cells and chondrocytes from 5 donor matched samples. Error bars indicate 





Figure 4.9: Collagen type I and II and toluidine blue staining. 
Representative patient 5 chondrogenesis of mixed population and progenitor cells from 
avascular and vascular meniscus and cartilage, assessed by staining sections using 
type I and type II collagen by immunohistochemistry. 
  
Figure 4.10:  Pellets staining intensity 
The semi-quantitative IHC analysis of mixed population and progenitor avascular and 
vascular meniscal cells and chondrocytes in collagen type I (A) and collagen type II, 





Cell-based therapies for meniscus tissue engineering are believed to play a fundamental 
role in the future meniscus regeneration strategies 181. Recent studies have supported 
the hypothesis that meniscus progenitor cells are the most effective cell type for 
meniscus regeneration, thought to be due to their tissue specificity and high 
histocompatibility 177. However, the characteristics of human meniscus progenitor cells 
including their cell morphology, proliferation rate, surface marker profiles, gene 
expression and isolation methods have not previously been comprehensively 
investigated.  
Morphologically, primary PAvas and PChs displayed the characteristic cobblestone 
shaped morphology, whereas PVas had an elongated fibroblast-like morphology. 
However, in the mixed population, cells presented with more extensive cytoplasmic 
processes compared to their progenitors. Chondrocytes that  displayed cytoplasmic 
process could be considered to have undergone a hypertrophic change, which is akin to 
changes observed in late-stage OA cartilage 206. Four of the five patient samples used 
in this study were derived from late-stage OA TKR samples, which might explain this 
distinct morphological feature noted in the mixed populations. However, the progenitor 
cells isolated from these OA tissues retained a typical proliferative fibroblastic 
morphology throughout the culture period assessed. 
Clonogenicity is a key feature of all types of stem cells derived from various sources 
including neural 207, hematopoietic 208, embryonic stem cells 209 and epidermal stem 
cells 210. In our study, progenitor cells from vascular meniscus regions were shown to 
proliferate at a significantly higher rate compared with the mixed population cells at 
passages 0-2. Cell-IQ® live cell imaging analyses of colony forming assays revealed 




colony forming potential, while the proliferation rate for PVas was significantly higher 
compared to PAvas and PChs. Seol et al. 202 created scratch and punch defects in an 
explant bovine meniscus, which showed the number of migrated progenitor cells in 
vascular region was 8.4 times higher than that in avascular region. These results 
indicated that PAvas, PVas and PChs possess a capacity for self-regeneration and that 
their endogenous cells display stem-like properties. Our results suggest that vascular 
meniscal progenitors proliferate faster than avascular meniscal progenitors and 
chondroprogenitors, which is might relate to the higher healing potential observed in 
the vascular meniscus region 189. However, based on the Cell-IQ® live imaging analysis 
of colony proliferation rates in PAvas, PVas and PChs, not every colony in the 
fibronectin coated wells showed a superior proliferation capacity. Indeed, 33.3% of 
colonies were not able to grow beyond 32 cells or doubled after 5 days culture. The cell 
numbers in these non-progenitor colonies levelled off or even decreased during the 48 
hours observed. Possible reasons for the presence of non-progenitor colonies might be 
that some non-progenitor cells which did not attached to fibronectin remained in the 
plate wells when media was taken out after 20 minutes. A few more rounds of PBS 
washing might help to reduce the number of residual non-progenitor cells, but it also 
poses a risk of washing away any attached progenitor cells. To improve the purity of 
meniscal progenitor cells in the future, cloning rings could be used to isolate 
monoclonal progenitor cells 148, although this technique is more cumbersome and 
doesn’t lend itself well to GMP practices for cell therapy manufacture.  
Gamer et al. 204 reported that progenitor cells migrate from mice meniscus explants and 
express stem cell markers such as CD44, CD90 and CD73. Shen et al. 211 characterised 
meniscus stem/progenitor cells by seeding the whole meniscus population at a very low 




highly expressed CD44, CD90, CD105, CD166. Our flow cytometry data showed that 
both whole mixed population and progenitor cells from avascular and vascular regions 
had high expression levels of CD44, CD73, CD90, CD105, CD166. Thus, these 
reported progenitor markers might not be specific to meniscus progenitor populations. 
However, our data supported that progenitor cells had a higher expression of integrin 
markers including CD49b, CD49c compared to the mixed population from avascular 
and vascular regions, as well as chondrocytes from donor-matched cartilage. Integrins 
are cell membrane receptors associated with cell adhesion and recognition that are 
essential to cell-cell and cell-ECM protein interactions 212. CD29 (integrin β1) is the 
most abundant integrin expressed by stem cells and chondroprogenitor cells 213. 
CD105+ BM-MSCs subpopulations with high expression levels of CD29 have been 
shown to have a superior chondrogenic capacity compared with cells that expression a 
lower percentage of CD29 157. A previous study also demonstrated that BM-MSCs have 
a high expression level of CD49c 214.  These findings support our results which indicate 
that integrin marker expression levels could be used to identify progenitor cells in 
meniscus tissues. In terms of our flow data the differences between avascular and 
vascular meniscal cells observed were consistent with the findings in our previous 
chapter (section 5.3), in that avascular meniscal cells had a higher expression level of 
the integrin markers CD49b and CD49c compared to vascular meniscal cells from n=10 
donor-matched meniscus tissues. The basic principles of the progenitors isolation 
protocol used in this chapter are based on the selection of cells that highly express β1 
integrins and demonstrate rapid adhesion to ECM proteins149. Previous studies relevant 
to meniscal progenitor cells have not reached a consensus on the progenitor cells 
isolation protocol. Table 4.3 summarizes the meniscus progenitor cells isolation 




widely from FACS sorting, selective adhesion, low seeding, tissue explant isolation etc. 
all successfully produced colonies. However, which of the protocols produced 
progenitor cells with a higher colony forming efficiency is unclear.  
Table 4.3: Meniscal progenitor cells isolation protocols 
Reference Tissue source Progenitor cells isolation protocol 
Osawa et al. 189 Meniscus from 
aborted human 
foetuses and TKRs 
Using FACS to isolate CD34 and CD146 
positive meniscal cells after meniscus tissue 
digestion 
Seol et al.202 Bovine Isolate progenitor cells that have migrated 
into injured sites in vitro, followed by trypsin 
and collagenase digestion 
Shen et al. 211 Bovine Meniscal cells were seeded at a very low 
density to form colonies (300 cells in one 
6cm dish) 
Gamer et al. 204 Mice Menisci explant culture: 50 μl essential 
media for 2 hours for tissue adhesion; 1.5 ml 
media culture for 3 days with additional 1.5 
ml media culture for 5-7 days. Meniscal 
progenitor cells migrate from explant. 
Huang et al. 203 Rabbit Suspend digested meniscal cells in stem cell 
growth media (DMEM, 20% FBS, 100 μl 2-
mercaptoethanol, 100 U/ml P/S) to make cell 
suspension, and culture for 8-10 days to form 
progenitor colonies. 
TKR: total knee replacement; FACS: fluorescence-activated cell sorting 
In the chondrogenic analyses undertaken in this study, the immunochemistry 
histological staining demonstrated that meniscal and chondrocyte progenitor cells were 
more effective at chondrogenesis compared with the mixed population cells. Type X 




the OA meniscus in a previous study 215 and in our work collagen type X gene 
expression was found to be significantly downregulated in progenitor cells. Together 
this might indicate that mixed population cells undergo hypertrophic differentiation as 
part of the progression of OA, whereas their progenitor counterparts do not. In addition, 
we found that progenitor cells generally produced higher amounts of GAGs compared 
with mixed population cells in terms of GAG/DNA analyses (significant difference 
only found between MVas and PVas). These findings suggest that the progenitor 
population in the meniscus is suitable cell source for use in rebuilding the proteoglycan-
rich avascular zone of damaged menisci, which represents key challenge for meniscus 
repair in the clinic 201. Interestingly, we found that the collagen type II staining intensity 
of PChs was significantly lower than MChs, which matched the gene expression level 
of collagen type II in PChs chondrogenic pellets, which was significantly down 
regulated compare with MChs chondrogenic pellets. The downregulation of collagen 
type II was seen as a sign of chondrocyte dedifferentiation 216. Typically, in vitro 
cultured human articular chondrocytes become dedifferentiated and lose their ability to 
produce hyaline cartilage tissue as their passage number increases 217. The 
dedifferentiation phenomenon of PChs may be caused by the inclusion of FGF2 growth 
factor in their culture media which is aimed at stimulating the proliferation of progenitor 
cells. Lee et al. 217 cultured costal chondrocytes in vitro with or without FGF2 
supplementation and demonstrated that the additional of FGF2 accelerated cell 
expansion and dedifferentiation. However, chondrocytes cultured with FGF2 
supplementation showed a better chondrogenic differentiation potential both in vitro 
and in vivo compared to chondrocytes cultured without FGF2. Therefore, the addition 
of FGF2 to culture media may have induced a rapid but reversible dedifferentiation 




found downregulated in progenitors compared with mixed population cells in most of 
patients, which may also correlate with the excessive dedifferentiation of progenitor 
cells. However, no consistent trending was found in the gene expression of collagen 
type I between progenitors and mixed population, which may be due to the fact of 
relatively small sample size. This was noted as a limitation in this study. 
In conclusion, our study demonstrates that the human meniscus contains meniscal 
progenitor populations that retains stromal cell-like phenotypes in both the avascular 
and vascular regions based on clonogenicity and chondrogenic differentiation capacity. 
Our results also suggested that meniscal progenitors derived from the vascular region 
of the meniscus exhibit stromal cell characteristics which likely associate with the better 
meniscal healing potential previously observed in the vascular region. The findings of 
this study build on the body of evidence which suggests that meniscal progenitors 
represent and attractive novel cell therapy strategy for the enhancement of meniscal 





Chapter 5: The influence of fibrin gel on the 
delivery of autologous meniscal cells in 
synthetic meniscus scaffold in an ovine 





Partial meniscectomy is the most common procedure to treat an irreparable meniscal 
tear and quickly relieve a patient’s symptoms 218. However, knee pain, grinding, 
clicking and instability are the most common symptoms that develop one year after 
meniscal surgery 218. To pursue a feasible meniscal substitute for a trimmed meniscus, 
fresh frozen allografts or synthetic meniscus implant such as Actifit® or the CMI®  have 
been used in the clinic. However, the use of MAT is found to have a high incidence of 
meniscal graft extrusion without clear evidence of chondroprotective effect 219, while 
both synthetic scaffolds have limitations post-implantation including graft shrinkage, 
lack of host tissue integration and up to 31.8% failure rate at a mean follow-up of 40 
months 84. A previous study demonstrated that patients who had a longer time from 
meniscectomy to meniscal transplantation presented with higher ICRS grades of 
cartilage damage 220. The knee joint is already in an early stage of osteoarthritis when 
meniscal transplantation is considered as a remedial intervention, which could be the 
main reason leading to graft failure. Therefore, we hypothesise that by performing 
meniscectomy and filling the gap with a meniscal substitute simultaneously could 
deliver a better clinical outcome. However, whether to proceed to a meniscectomy or 
meniscus repair procedure is usually quickly decided by surgeons depending on their 
experience and also the meniscal tear pattern, assessed during the arthroscopic 
examination. Thus, meniscal allografts which require matching the donor to the 
recipient’s size and depending on the available resource from a tissue bank are often 
not suitable in this clinical scenario 221. In addition, the partial synthetic meniscal 
scaffolds have certain limitations as mentioned above. New meniscus implants are 
required to withstand the physiological stress, strain and loads that exist within the knee 




these clinical available scaffolds may overcome these challenges. 
Autologous meniscal cells are considered an ideal cell sources to enhance meniscal 
regeneration 104, with the major advantage of using in situ derived cells being good 
histocompatibility 181. Autologous meniscal cells could be isolated from trimming 
meniscal tissue during a meniscectomy and then reinserted with a carrier back into the 
patient. To enhance the cell attachment within the scaffolds and to make it easier to 
manipulate cells during the implantation procedure, a biological cell-delivery vehicle 
needs to be developed. Fibrin gel is a biocompatible, biodegradable, injectable 
biomaterial which is generally considered not to be toxic, allergenic or immunogenic 
222. It has been shown to facilitate cell attachment, proliferation, differentiation and 
tissue formation in a rabbit model of cartilage repair 223. Therefore, implanting cells 
with fibrin glue could induce a synergistic effect for meniscus tissue repair. 
The purpose of this chapter was to explore the feasibility of seeding autologous 
meniscal cells carried by a fibrin gel into the polyurethane scaffold (Actifit®) to enhance 
tissue formation, using an in vitro sheep meniscus explant model. We hypothesised that 
using fibrin gel to deliver autologous meniscal cells combined with the clinical 
synthetic meniscus scaffold would improve neotissue formation in a meniscal punch 
defect. 
5.2 Experiment design 
Fast green dye was mixed with fibrin gel to indicate the fibrin gel distribution within 
the scaffold as described in chapter 2.9.2. To assess the cell proliferation and viability 
in the Actifit® scaffold with and without fibrin gel, an initial pilot experiment was 
performed. For this there are three groups, (i) scaffold only (negative control group), 




delivered by fibrin gel (fibrin gel group). For the pilot study the constructs were cultured 
for 14 days, after which cell viability in the scaffold was assessed using a LIVE/DEAD 
viability/cytotoxicity assay kit and imaged under a confocal microscope as described in 
chapter 2.9.3. The chondrocytes delivered by fibrin gel using the same protocol were 
also seeded in CMI® scaffold for 30 minutes and sacrificed for histology analysis to 
assess the cells distribution within scaffold. 
For the main experiment to test our hypothesis that fibrin gel would enhance meniscal 
cell delivery and function, a sheep meniscus explant model was used for implanting the 
different groups into, similar to the pilot study but using cells isolated from the 
avascular region of the meniscus (i) scaffold only, (ii) scaffold with meniscal cells and 
(iii) scaffold with meniscal cells in fibrin gel. This is shown in Figure 5.1. Five pairs of 
sheep knee joints (stifle joint) were obtained within 12 hours of sacrifice from animals 
ranging in age from 11 months to 3 years (Figure 5.2A). Two lateral menisci and two 
medial menisci were harvested from each sheep (Figure 5.2B), and washed three times 
with PBS supplemented with 1% P/S. The inner avascular region of each medial 
menisci was dissected and minced, following by overnight digestion in type II 
collagenase in serum-free medium at 37 °C. Digested suspensions were passed through 
a 40µm cell strainer to remove tissue debris and centrifuged at 1000 g for 10 minutes. 
Avascular meniscal cells were counted with a haemocytometer and trypan blue. Cells 
were seeded at a density of 5 x 103 cells/ cm2 in tissue culture flasks in complete culture 
media. Cells from the avascular menisci of all five sheep were expanded to passage one 
prior to seeding into explants.  
For all five donors, both lateral menisci were stored at -20°C until cell seeding stage. 
All menisci were vertically sectioned into quarters. A 3mm core ‘defect’ was created to 




samples were incubated in 6 well plates in 3 ml of culture media at 37°C and 5% CO2. 
The same size core scaffolds were obtained from the Actifit® scaffold and primed in 
culture media for at least 24 hours on a roller before insertion into meniscus defects. 
Each of the three groups in the experiment ( (i) negative controls, (ii) cells and (iii) 
fibrin gel) were performed in triplicates for each group). In the cell group, sheep 
avascular meniscal cells were resuspended in 100μl of media at a concentration of 5 x 
106 cells/ml and loaded onto scaffolds. In the fibrin gel group, sheep avascular meniscal 
cells were resuspended in 75μl of fibrinogen (100mg/ml) at a concentration of 6.7 x 106 
cells/ml and injected into the scaffold cores, followed by adding 25μl of thrombin 
(100U/ml) with 100U/ml aprotinin (A1153, Sigma-Aldrich, UK) supplement. The 
explant constructs were incubated at 37° C for 30 min to facilitate cellular attachment 
and polymerisation of the fibrin gel (Figure 5.2D). Subsequently, a further 3 ml of 
complete culture media was added to all wells. Explants were incubated at 37°C, 5% 
O2, and 5% CO2. 
After 28 days of culture, two scaffolds from each group were removed from the 
meniscal explant. One scaffold was used to extract mRNA and triplicate qRT-PCR tests 
were performed to assess the gene expression level of collagen type I (COL1A2), 
collagen type II (COL2A1), aggrecan (ACAN), SOX-9, collagen type X (COL10A1) 
as described in chapter 4.7.Gene expression level of the fibrin gel group and the cells 
group were normalised to GAPDH, then the relative changes of fibrin gel group to cells 
group was presented using the comparative threshold method. A 2-fold up- or 
downregulated change was considered biologically significant. The other scaffold was 
used to measure the total GAG and DNA content using the DMMB and PicoGreen 
assay as described in chapter 4.6. Finally, the amount of GAGs were normalised to the 




from each group was fixed and processed for wax embedding and sectioned at 6µm 
thickness (Chapter 2.8.2). Immunohistochemistry staining was performed for collagen 
type I and II to evaluate the matrix formation (Chapter 2.8.5). 
 






Figure 5.2: Sheep meniscus explant process 
(A) Overview of a sheep knee joint (stifle); (B) two pairs of lateral and medial sheep 
menisci from left and right knees; (C) the lateral meniscus was section into four pieces 
to create a 3mm diameter punch defect in each; (D) 3mm diameter core of an Actifit® 
scaffold was inserted into the meniscus defect and used for the one of the experimental 






5.3.1 Fibrin gel distribution and cell viability in the scaffold 
After 30 minutes of polymerisation, the Actifit® scaffold was sectioned vertically into 
halves. The fast green dye indicated that the fibrin gel had penetrated the scaffold 
throughout, with an even distribution across the whole construct (Figure 5.3). After 14 
days in culture, LIVE-DEAD imaging demonstrated that the fibrin gel group had a 
higher density of chondrocytes in the scaffold compared to the cells alone group, which 
had lower cell number and diminished viability (Figure 5.4B & Figure 5.4C). Figure 
5.5 showed the chondrocytes delivered by fibrin gel in CMI® scaffold evenly 
distributed with in the scaffold. 
 
Figure 5.3: Fibrin gel penetration test 
The fast green dye shows that the fibrin gel had penetrated with complete scaffold 






Figure 5.4: Live/dead staining of scaffold 
Cell viability demonstrating live cells with green fluorescent staining. No staining was 
seen in acellular scaffolds (A), some staining was present in the scaffolds seeded with 
chondrocytes alone (B), but the group that showed the highest number of viable cells 
retained in the scaffold, was the fibrin seeded scaffolds after 14 days in culture (C). 
Some red (dead) cells can also be seen in (B) and (C). 
 
 






5.3.2 Imaging of cell-seeded scaffolds in the in vitro explant model 
The ovine meniscal explants with seeded scaffolds were observed and imaged under 
light microscopy after 14 days and 28 days in culture (Figure 5.6). At day 14, culture 
expanded avascular meniscal cells were seen mostly growing around the meniscus 
explant, attached to the tissue culture flask in the cell alone group (Figure 5.6A), 
whereas cultured avascular meniscal cells were well retained within the fibrin gel 
seeded scaffold (Figure 5.6B). At day 28, there was no evidence of  the meniscus 
explant tissue attaching to the scaffold (Figure 5.6C). Seeded avascular meniscal cells 










Figure 5.6: Sheep explant culture images 
Sheep meniscus explants viewed under a phase contrast light microscope at day 14 (A, 
B) and day 28 (C, D). Avascular meniscal cells favoured growing on tissue culture 
plastic in the cell only seeded group (A, C) compared to the fibrin gel seeded group, 
where the cells appeared generally be retained within the fibrin gel initially (B), before 
migrating out at day 28 (D). M: meniscus tissue, S: commercial scaffold cores. Yellow 
dashed line: margin between meniscus and scaffold 
 
5.3.3 Gene expression of meniscal cells in the meniscus explant model 
After 28 days, RT-qPCR analysis of RNA extracted from the meniscus explant cultures 
was performed. Figure 5.7 shows the gene expression of the fibrin gel group relative to 




were significantly upregulated in sheep 1, 2 and 4, but downregulated in sheep 3. The 
expression level of aggreccan significantly downregulated in sheep 1 and upregulated 
in sheep 2. Levels of expression for collagen type I were significantly upregulated in 
sheep 3 and downregulated in sheep 4, while the levels of collagen type II were 
significantly upregulated in sheep 1 and 3. 
 
Figure 5.7: Gene expression profiles of extracted mRNA in cell only group and fibrin 
gel seeded scaffold in the meniscus explant model.  
Data shown are the expression levels of the fibrin seeded group expressed relative to 
cell only seeded group.  
 
5.3.4 Matrix formation assessments in the sheep meniscus explant model  
After 28 days in culture, the total GAG and DNA production in the scaffolds were 




amount of GAGs in the group fibrin gel seeded group were twofold higher than cell 
only group (p<0.001) and eightfold higher than the acellular group (p<0.001) (Figure 
5.8A). The total DNA was also highest in the fibrin seeded group, being significantly 
higher than both the cell only and acellular group (p<0.001) (Figure 5.8B). Avascular 
meniscal cells delivered by fibrin gel had a higher production of GAGs compared to 
those in the cell only group, in which cells were applied directly to the scaffold without 
a carrier, in terms of GAG/DNA (p=0.0085) (Figure 5.8C). Additionally, the evaluation 
of collagen type I deposition via immunochemistry demonstrated more matrix 
formation in the fibrin gel seeded scaffolds (Figure 5.9 E&F) compared to the cell only 
group (Figure 5.9 C&D), with no staining present in the acellular negative control 






Figure 5.8: Biochemical component analysis of sheep explant models 
Quantitation of GAG (A), DNA (B) and GAG/DNA (C) in explant cultures of no cell, 






Figure 5.9: Immunochemistry staining of collagen type I in explants and scaffolds.  
(A) Acellular negative control sample showed no matrix formation within scaffold; Cell 
only group (B) showed less collagen formation within scaffold compare to fibrin gel 
seeded group (C); (D) IgG negative control staining; S: Actifit® scaffold, M: sheep 





The goal of this in vitro study was to assess the feasibility of delivering autologous 
meniscal cells together with a fibrin gel carrier to enhance meniscus regeneration for 
partial meniscus replacement. The study firstly examined the cell distribution and 
viability with or without fibrin gel delivery in the polyurethane scaffold. Contiguously, 
we used a sheep meniscus explant model to assess cell seeded scaffold matrix formation 
in autologous meniscal cell seeded scaffolds with or without fibrin gel as a carrier. 
Many of findings suggest that fibrin gel could be used as a cell delivery vehicle in 
meniscus scaffolds as a treatment strategy that could be applicable for use in the clinic 
for promoting meniscus regeneration. 
Whilst the Actifit® meniscal implant is used clinically and provides relief of symptoms 
and benefit for 87.6% patients, it is not usually a permanent solution and pain and 
disability commonly return within years post-treatment 224. If this scaffold could be 
successfully populated with cells, they may be able to ensure longer or perhaps even a 
permanent benefit to patients. Actifit® is a PU and PCL based scaffold previous studies 
have demonstrated that PU by itself is a poor substrate for cells to adhere to 225. Fibrin 
gel as a biopolymeric material provides various advantages including excellent 
biocompatibility, promoting cells attachment, degrading in a controllable way and is 
commonly used clinically 226. Scotti et al. 131 bonded two swine meniscal slices with 
chondrocyte in a fibrin gel hydrogel and implanted it in a nude mouse model for 4 
weeks. They found a firm bonding at the interface with new fibrocartilaginous tissue 
formation. Our pilot experiment with LIVE-DEAD imaging of the cell group and fibrin 
gel group demonstrated that delivering cells within a fibrin gel resulted in significantly 
more live cells being retained within the PU scaffold. Imaging of the meniscus explants 




carrier before day 13 and gradually migrated out from fibrin gel up to day 28. Therefore, 
fibrin gel fulfils the objective of retaining cells implanted within scaffold; this is likely 
to be important in the clinical scenario where it would keep the cells in position 
allowing them to maximise the cells function for meniscus tissue regeneration. In 
addition, fibrin gel as a cell carrier could also improve the implanted cell integration to 
the host tissue. Previous study has demonstrated that chondrocytes delivered by fibrin 
gel into a porous poly(vinyl alcohol) hydrogel (PVA-H) significantly enhanced the 
integration strength of three-layered constructs (PVA-H between devitalized 
cartilage)227. However, we didn’t compare the integration strength between fibrin gel 
group and cells groups in our study. A push out mechanical test could be implemented 
in the future study. 
The varies gene expression level in fibrin gel groups compare to cell groups in different 
donors were noted in our results. Only SOX-9 showed a consistent upregulation in most 
donors in fibrin gel group. One of the possible reasons may be due to the wide range of 
donor age (11 month – 3 years old). Clark et al.228 reported the large diversity of gene 
expression level in different developmental stages in the domestic sheep. We will select 
the similar age donor for the future study to have comparable results. This was also 
noted as a limitation of the study. 
Improved matrix-forming capacity of cells implanted within fibrin gel was also 
indicated, with higher levels of GAGs measured within the polyurethane scaffold 
loaded with fibrin gel compared to when cells were applied alone. In addition, the 
higher DNA content in the fibrin gel group proved that this delivery system promoted 
increased meniscal cell proliferation, whilst the higher GAG/DNA ratio demonstrated 
that individual cells contributed greater matrix production when delivered in fibrin. On 




compared with fibrin gel group. Our observation during the explant culture 
demonstrated that the majority of seeded cells adhered to culture flask instead of the 
scaffold. Tarafder et al.229 demonstrated that without the growth factors stimulation in 
meniscus explant defect site, no migrated synovial MSCs seeded underneath explant 
could migrate into injury site. Therefore, in our experiment, the exceeded cells growing 
on the flask unlikely contribute to the matrix production in cells group as previous study. 
Pawelec et al. 230 seeded ovine meniscal cells into aligned or isotropic collagen type I 
scaffold with or without fibrin gel delivery. This study showed a similar increase in cell 
metabolism and cell proliferation in aligned collagen scaffolds when the cells were 
delivered with fibrin. They also reported on the proliferation of cells within the fibrin 
gel alone, which didn’t show the encouragement of high proliferation or metabolic 
activity over three weeks which probably due to the early dissolution of fibrin gel 230. 
In our experiment, we mixed thrombin with aprotinin which could significantly reduce 
fibrin degradation 231. Aprotinin is a serine protease inhibitor to prohibit fibrinolysis by 
blocking plasmin formation 232. Aprotinin is also a key component of a clinically 
approved fibrin sealants (TISSEEL, Baxter, Deerfield, IL) which has been widely used 
in the cell therapy for cartilage repair (ACI) 233,234. 
The current experiment proved the feasibility of using autologous avascular meniscal 
cells in an ovine explant model. In the clinic these autologous meniscal cells could be 
derived from discarded meniscus tissue of patients undergoing partial meniscectomy. 
One of the major controversies of using autologous meniscal cells for cell-based 
meniscal therapy is donor site mobility 104. Unlike in ACI, where a biopsy of ‘healthy’ 
cartilage is harvested to source the chondrocytes, the rim of meniscus is, which the ideal 
source of meniscal cells is essential for meniscus replacement suturing 235. However, 




the trimmed meniscus tissue, which is usually from the avascular region, can be used 
as is an ideal cell source to obtain autologous avascular meniscal cells. Jiang et al. 236 
showed that immediate MAT after meniscectomy led to more satisfactory subjective 
outcomes, including less joint degeneration and less muscle strength deficits compared 
to delayed MAT (average 35 months after meniscectomy) with 4-6 year follow-up. This 
combined procedure fills the time gap usually experienced between meniscectomy and 
meniscus transplantation, during which many patients develop further pain and return 
for further treatment.  
There remain many further questions to answer, for example, what number of meniscus 
cells will be required? If more are needed than the number obtainable from discarded 
tissue is not sufficient, coculture with other cell populations could be a possibility. Co-
culture of primary meniscal cells with BM-MSCs has been considered as a strategy to 
maintain the differentiated phenotype of primary meniscal cells with the additional 
benefit that MSCs may contribute to produce functional matrix components of the 
meniscus and downregulate hypertrophic differentiation of MSCs 118,237. A recent 
clinical study has shown the safety and feasibility of using a combination of chondrons 
with allogeneic BM-MSCs for cartilage repair 238. Hagmeijer et al. 239 co-cultured 
human meniscal cells and BM-MSCs in different ratios in pellets with a type I collagen 
hydrogels. They reported that coculturing 20% meniscal cells and 80% MSCs produced 
the highest GAGs and collagen content.  
A one-stage procedure for meniscus cell therapy would be cost effective and a lower 
patient burden. To achieve that, a rapid digestion of meniscus tissue during the surgical 
procedure is required. Numpaisal et al. 240 rapidly dissociated bovine meniscus tissue 
with different concentration collagenase type II for 30 mins and then fragmented with 




collagenase. Their results suggested that 0.2% (w/v) rapidly digested cells had highest 
cellular metabolism up to day 7. This finding could be combined with the in vitro results 
in this chapter, allowing the design of a more strategic experiment in the future which 
could use fibrin gel to deliver a mixture of rapidly digested meniscal cells and BM-
MSCs to the PU scaffold for a one-stage cell-based therapy for meniscal regeneration. 
In the current study, histological processing of the Actifit® scaffold was problematic. 
Our histopathology laboratory regularly uses xylene in processing the tissue ready for 
wax embedding and it also uses it to deparaffinise wax sections. However, when we 
used xylene to prepare the Actifit® scaffold in an automated processor, the scaffold was 
severely affected and appeared with holes and cracks when embedded in paraffin. The 
reason for this may reflect Actifit® composition of 20% PU and 80% PCL which could 
be dissolved in the xylene and subsequently cause the collapse of the scaffold during 
the vacuum phase used in the embedding process 241. The cracks surrounding the 
scaffold in the paraffin wax was caused by the incomplete dehydration of water and 
penetration of paraffin probably due to the hydrophobic property of the polymer 
material. To overcome these difficulties, we carefully transferred the samples between 
xylene and IPA to maintain the structure before wax embedding. In addition, we 
increased the dehydration time in IPA to completely remove the water content and the 
time emerged in paraffin to encourage the thorough penetration of the scaffold. Another 
issue we found was that the Actifit® scaffold peeled off the slides when dewaxing in 
xylene. To address this issue, we used Histo-Clear II (aliphatic hydrocarbons and d-
limonene) which is less brittle, non-toxic and non-volatile as a xylene substitute 101. 
Cryosectioning was also attempted for the Actifit® scaffold. However, the scaffold 
shattered during cryosectioning. 




autologous avascular meniscal cells in a clinical grade meniscus substitute in vitro. 
Cells delivered by fibrin gel showed an increased cell proliferation and more matrix 
production within the scaffold compared to cells directly seeded into the scaffold in the 
absence of fibrin. The results of these experiments represent the foundation of this 
approach of augmenting the benefit of a commercially available meniscal implant with 
the addition of a cellular component; this biological approach may to increase the 
longevity of the initial benefit gained from the scaffold alone if it contributes to the 





Chapter 6: Concomitant autologous 
chondrocyte implantation with synthetic 
meniscus scaffold or allograft 





Meniscal and chondral lesions are common consequences of acute or chronic 
musculoskeletal trauma 242. These injuries often lead to joint pain and instability, which 
can trigger the early onset of knee OA. In addition, patients with combined meniscal 
and chondral lesions have shown an increased risk of developing knee OA compared 
to patients with a single tissue pathology 243. The most widely used treatments for 
patients who present with meniscus deficiency and unicompartment arthritis include 
osteotomy, unicondyle or total knee replacement 244.  
Meniscus allograft transplantation (MAT) has shown promising results in the treatment 
of patients who had partial or complete meniscectomy and has been suggested to delay 
articular cartilage degeneration in a mean of 12.3 years follow-up study 245. An 
alternative procedure to manage pain developed after partial meniscectomy, restore 
knee biomechanics and delay the onset of OA is the use of a polyurethane (Actifit®) or 
collagen (CMI®) meniscal substitute, which can be implanted arthroscopically 84. ACI 
has been used at our centre for over 20 years and in over 500 patients for the treatment 
of knee cartilage injuries and early OA. We have previously reported the mid-term to 
long-term outcome of ACI 246, showing that knee function rapidly improves over the 
first 15 months, after which functionality remained constant for up to 9 years. More 
recently, others have shown ACI survival rates of 78% at mid-term and 51% beyond 
ten years following ACI 247.  
Untreated cartilage defects can lead to excessive loading of meniscus implants, which 
is frequently responsible for early meniscus graft failure 220. We hypothesise that 
performing a multi-faceted surgical/biological treatment by combining either MAT or 
meniscus substitute implantation with ACI could slow the progression of OA without 




have presented the short to midterm follow up data on patients who have undergone 
combined MAT and ACI procedures 248,249. Farr et al 248 reported 36 patients with four 
failures at a minimum of 2 years follow up, while Ogura et al 249 presented 18 patients 
with six failures at an average of 7.9 years follow-up. Both studies demonstrated a 
significant improvement in both symptoms and knee function. However, to the best of 
our knowledge, no study has reported any clinical outcome on the combined treatment 
of partial meniscus implantation with concomitant ACI. 
Our group has previously reported a small pilot study of eight patients treated with a 
combination of MAT and ACI with an average of 3 years follow-up 250. Longer-term 
follow-up is needed to determine the full potential of this technique. This study 
therefore aims to present the mid to long-term follow-up on these first eight and 
subsequent cases, as well as investigating patients who have received concurrent ACI 





6.2 Methods and Materials 
6.2.1 Patient Information 
We reviewed the data from all patients who had undergone ACI with MAT (20 patients) 
or a polyurethane meniscus scaffold implantation (8 patients, Actifit®, Orteq Ltd, 
London, UK) between 1999 and 2018 (Table 6.1). Patients with less than 2 years 
follow-up were excluded. All patients provided informed consent before surgery. All 
patients consented to an ethically approved project (REACT 09/H1203/90, approved 
by South Staffordshire Local Research Ethics Committee, UK). 
6.2.2 Surgical Techniques 
The procedure was performed in two-stages. In the first stage, the partial or complete 
absence of a meniscus and the presence of cartilage lesions were confirmed. A cartilage 
harvest for ACI was obtained from the femoral trochlea, which was transported to our 
MHRA (Medicines and Healthcare Products Regulatory Agency)-licensed GMP 
manufacturing facility. Chondrocytes were isolated and expanded in vitro to a 
second/third passage as previously described 147.  
In the second stage, an arthrotomy was performed via either a medial or a lateral 
parapatellar incision depending on the compartment involved. Chondral defects were 
trimmed to stable edges and covered with periosteum or by a resorbable porcine 
collagen membrane (Chondro-Gide®-Geistlich Pharma AG, Division Biomaterials, 
Switzerland). The patches were sutured onto the peripheral cartilage and sealed with 
fibrin glue (Tisseel, Immuno AG, Vienna, Austria). The cultured autologous 
chondrocytes were injected beneath the patch in a suspension of the patient’s own 
serum. 




was performed and an allogeneic cryopreserved meniscus with small bone plugs at 
either end was placed on top of the tibia and secured by sutures in the bone tunnels. 
Further sutures were used to secure the allograft to the capsule laterally in order to hold 
the allograft in the load-bearing position 250. From 2012 on, the allograft transplantation 
was performed using an arthroscopic technique. For medial meniscal transplant, the 
anterior and posterior horn of allograft was fixed through the tibial tunnel. For lateral 
meniscal transplant, the central roots were arthroscopically secured with a dovetail bone 
technique, while the body of the meniscus for both were fixed to the capsule with a 
combination of all inside, inside-out and outside-in sutures.  
For Actifit® scaffold implantation, all procedures were performed arthroscopically prior 
to open arthrotomy for ACI. Briefly, the residual meniscus was debrided while the 
peripheral rim was preserved. Following the measurement of the meniscus defect, the 
Actifit® scaffold was shaped to the required size + 10% and secured with a combination 
of meniscal repair kit (FasT-FixZR®, Smith&Nephew, Andover, USA) and inside-out 
and outside-in sutures. 
The size and site of the treated concomitant cartilage defect was documented using the 
validated Oswestry Knee Map 251. The OsCell Rehabilitation protocol for the ACI 
procedure was followed post-operatively, limiting knee flexion to 45° for three weeks 
and allowing full weight bearing after 12 weeks 252. 
6.2.3 Outcome Assessments 
All patients were evaluated pre-operatively and post-operatively with a modified 
Lysholm score (range 0-100 where 0 is worst and 100 best) (appendix IV) 253. Scores 
were collected at yearly intervals post-operatively during an outpatient follow-up or by 
a postal questionnaire. The overall survival rate of the two groups of patients was 




defined as ACI and/or MAT graft failure with revision of either cartilage repair or MAT 
or total knee arthroplasty. Patients also answered a question regarding their one-year 
satisfaction score with the procedure (1-4, 1 poor, 4 satisfied).  
Post-operative MRI scans were evaluated by a musculoskeletal radiologist. A 
previously validated measurement was used to assess the relative meniscal extrusion 
(rME), coronal cartilage coverage index (cCCI) and sagittal cartilage coverage index 
(SCCI) 254. Briefly, the absolute meniscal extrusion (aME) was measured on the coronal 
plane through the centre of the tibiofemoral joint, as the distance from the meniscal 
margin to tibial margin, excluding any osteophytes (Figure 6.1A). On the same view, 
the rME was calculated as the ratio of aME over total meniscus width. On the sagittal 
view through the centre of the tibiofemoral compartment, the extrusions of the anterior 
and posterior meniscal horns were also measured (Figure 6.1B). On the same sagittal 
and coronal views, CCCI and SCCI were measured as the percentage of tibial cartilage 






    
Figure 6.1: Illustration of meniscus extrusion measurement.  
(A) Measurements of absolute meniscal graft extrusion (aME) in the coronal plane (a), 
meniscus graft width (b), coronal width of tibia plateau (c); relative meniscal extrusion 
(rME)= a/b, coronal cartilage coverage index (cCCI)= [b-a]/c. (B) measurement of 
extrusion (a, e) and non-extrusion (b, d) of anterior and posterior meniscus graft, 
sagittal width of tibia plateau (c); sagittal cartilage coverage index (sCCI) =[b+d]/c. 
 
Biopsies of meniscus were taken at arthroscopy using a Jamshedi juvenile bone marrow 
biopsy needle (1.8mm diameter), with a video recording of the procedure for 13 out of 
20 patients in the MAT treated group between 12 and 24 months postoperatively. A 
full-depth cartilage biopsy was taken through to the subchondral bone, where possible. 
Meniscus biopsies were taken radially in the horizontal plane from the outer surface to 
the centre. Samples were snap frozen in liquid nitrogen-cooled hexane and 
cryosectioned (7μm) and stained with H&E and TB or safranin O & fast green to assess 




6.2.4 Statistical Analysis 
Mann-Whitney U tests and unpaired Students t tests were used to compare the age, BMI, 
length of follow-up, rME, cCCI and sCCI of the two groups. One-way ANOVAs were 
used to compare the improvement in Lysholm scores with time. Kaplan-Meier survival 
curves were used for survival analyses. A multilevel model was used to estimate mean 
Lysholm scores for the two groups at 2-, 5- and 10-year follow up. For this model, 
treatment group and preoperative Lysholm scores were considered as fixed effects and 
patients as random effects. GraphPad Prism (Version 8.30, San Diego, USA) was used 
for all statistical analyses other than the multilevel model, for which we used R vs 4.0.2 
(R Foundation for Statistical Computing, Vienna, Austria) and the packages nlme and 
Emmeans. For all statistical tests, a two-tailed p-value below 0.05 was considered 





6.3.1 Patient Demographics 
The MAT group comprised 17 males and 3 females (5 medial, 15 lateral) with a mean 
age at surgery of 40.2 ± 9.0 years (range, 28-58 years). The Actifit® group had 7 males 
and 1 female (4 medial, 4 lateral) with a mean age at surgery of 42 years (range, 31-65 
years) (Table 6.1). The mean follow-up for the MAT and Actifit® groups was 7.94 years 
(range, 2-20 years) and 7.2 years (range, 2-10 years), respectively. No significant 
difference was found in Body Mass Index (BMI) between the two groups (p=0.058).  
There were 11 patients in the MAT group and three patients in the Actifit® group who 
had bipolar (kissing) lesions. In the MAT group, the mean size of the femoral defects 
was 6.6 cm2 (range, 1-12.3 cm2) and on the tibia was 5.7 cm2 (range, 1.1-10.5 cm2). In 
the Actifit® group, the mean size of femoral defects was 2.7 cm2 (range, 0.25-8 cm2) 
and on the tibia was 6.6 cm2 (range, 0.5-12 cm2).  
Table 6.1: Patient Demographics 
  MAT Actifit® 
Age at surgery, y, mean ± SD 40.2 ± 9.0 42.0 ± 11.0 
Sex: male/female, n 17/3 7/1 
Right/left knee, n 16/4 5/3 
Body mass index, kg/m2, mean ± SD 
(range) 
29.4 ± 5.2 
(22.3 – 45.6) 
25.7 ± 2.8 
(22.4 - 30.5) 
Follow-up, years, mean ± SD  7.9 ± 6.1 7.2 ± 3.5 
Unipolar / Bipolar cartilage lesion, n 9/11 5/3 
Cartilage lesion size, cm2, mean ± SD 6.3 ± 3.3 4.1 ±5.1 








6.3.2 Concomitant and Subsequent Surgical Procedures 
Three patients in the MAT group had concomitant procedures (3 osteotomy) and two 
patients in the Actifit® group (2 osteotomy, 1 ACL reconstruction) at the same time as 
ACI and meniscal replacement. Eleven of the 20 patients (55%) in the MAT group and 
1 of the 8 patients in the Actifit® group (12%) required subsequent surgical procedures 
(43% in total), including osteotomy, microfracture and joint debridement. Six of the 11 
patients in the MAT group requiring subsequent procedures had a failure of their MAT 
procedure later and needed a TKR. 
6.3.3 Clinical Outcomes Analysis 
In the MAT cohort, the mean pre-operative Lysholm score was 48 ± 17, which 
significantly increased to a mean of 66 ± 16 at one-year post-treatment (p=0.0002) 
(Figure 6.2A). Similarly, in the Actifit® group, the mean pre-operative Lysholm score 
was 54 ± 21 which significantly rose to 79 ± 11 at one-year post-operation (p=0.0073) 
(Figure 6.2B). The mean one-year satisfaction scores for the MAT and Actifit® groups 
were 2.8 ± 1.1 and 2.5 ± 1.2, respectively. At the latest follow up to 2020, a total of 6 
procedures were considered failures in the MAT group at a mean of 7.2 ± 3.3 years 
(range, 3-12 years; Table 6.2), while no patient had revision or arthroplasty procedure 
in the Actifit® group. All 6 of the failed MAT procedures had converted to a total knee 
replacement due to the progression of OA. Overall, the survival rate for the MAT group 
was 95% at 5 years and 71% at 10 years, while for the Actifit® group, survival was 100% 
at 5 years and 83% at 10 years (Figure 6.3). However, this difference between the two 





Figure 6.2: Comparison of pre-operative and one-year post-operative Lysholm score 
for MAT (A) and Actifit® group (B).  
 
 
Figure 6.3: Kaplan-Meier survival curves.  
Failure was defined as the need for revision surgery or total knee replacement due to 
ACI and/or meniscus graft failure or as a result of osteoarthritis progression. ACI: 
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Lateral Bi DFO 5.5 
DFO, distal femoral osteotomy; LFC, lateral femoral condyle; LTP, lateral tibial 
plateau; M, male; MFC, medial femoral condyle; MTP, medial tibial plateau. 
6.3.4 Multilevel Modelling and Estimated Clinical Outcome  
Multilevel modelling demonstrated that a higher pre-operative Lysholm score was 
significantly associated with a higher post-operative Lysholm score (p=0.0034) (Table 
6.3). The estimated post-operative Lysholm score model showed that the two groups 
had comparable functional scores at 2, 5 and 10-year follow up, with no significant 






Table 6.3: Fixed Effects in the Longitudinal Multilevel Model 
Fixed effects 
Mean Value of  
Coefficient (95% CI) 
P value 
Pre-op Lysholm score 1.83 (0.68, 2.98) 0.0034 
Graft type (Allograft-Actifit®) -0.83 (-15.60, 13.93) 0.9088 
Monthly rise after one year 0.02 (-0.12, 0.15) 0.8204 
Monthly rise after one year: graft type -0.04 (-0.19, 0.11) 0.6089 
CI: Confidence Intervals. 
Table 6.4: Estimated Post-operative Lysholm Scores  
Graft type 2-year (95% CI) 5-year (95% CI) 10-year (95% CI) 
MAT 64.8 (58.0, 71.5) 63.9 (57.3, 70.5) 62.4 (53.8, 71.0) 
Actifit® 66.6 (55.2, 77.9) 67.1 (56.0, 78.3) 68.1 (52.8,83.3) 
 
6.3.5 Radiographic Evaluation 
Twelve patients in the MAT group (mean 6.71 ± 4.6 years) and 5 patients in the Actifit® 
group (mean 2.78 ± 2.0 years) had post-operative MRI evaluation. No significant 
differences between the two groups were found in rME, cCCI or sCCI (Figure 6.4 A, B 
and C). Figure 6.5 represent the postoperative MRIs of  Actifit implant with ACI patient 
at one-year (Figure 6.5A) and five-year (Figure 6.5B). The Actifit scaffold has a slightly 
hyperintense signal with intact morphology at one year follow-up, whereas the signal 
of scaffold appeared less intensive and the size of scaffold shrunk with a small vertical 





Figure 6.4: MRI assessment of meniscus extrusion. 
(A) relative meniscal extrusion and cartilage coverage percentage on coronal (B) and 
sagittal plane (C) in MAT and polyurethane scaffold groups. rME: relative meniscal 






Figure 6.5: Represent postoperative MRI (sagittal) of Actifit implants with ACI 
patient.  
(A) One-year postoperative MRI well visualized the intact Actifit scaffold at posterior 
horn of lateral meniscus. (B) Five years postoperative MRI showed smaller scaffold 
remnant with a vertical tear on the same plane, but the signal changed less intense 
compared to one-year postop. 
 
6.3.6 Post-operative Meniscus Allograft Biopsy Histology Evaluation 
Thirteen out of 20 patients in the MAT group had a post-operative histological analysis 
of the meniscus and treated cartilage defect. None of the Actifit® group had post-
operative biopsies. H&E staining of allograft implants demonstrated fibrocartilage, 
which was well populated with cells in all cases. Vascularisation could be observed in 
some cases (Figure 6.6A). The presence of proteoglycans throughout the tissue was 





Figure 6.6: Representative histology of biopsies taken 19 months post-operation with 
allogeneic meniscus  
(A-C): H&E staining (A) demonstrated numerous cells in the meniscus matrix with 
blood vessels (arrow); Safranin O & Fast green (B) and toluidine blue staining (C) 






In this retrospective case series of mid to long-term follow up, we analysed data from 
28 patients who underwent ACI combined with MAT (20 patients) or with a 
polyurethane meniscus scaffold (Actifit®, 8 patients) for the treatment of concomitant 
cartilage lesions and meniscal deficiency. Overall, both groups of patients showed 
significant improvement in terms of pain relief and functional scores up to 20- and 10-
years post-treatment for the MAT and Actifit®, respectively. Based on clinical outcome 
analysis and statistical modelling, we found that both groups of patients had a similar 
recovery pattern, in which the patients’ knee function recovered rapidly in the first year, 
levelling off subsequently. This biphasic recovery pattern was also shown in a cohort 
study of 80 ACI only-treated patients from our group, which showed a short phase I 
rapid recovery (in the first 15 months), followed by a longer phase II slow recovery (up 
to 9 years) 246. 
To our knowledge, this is the first study that has evaluated the clinical outcomes of 
combined partial meniscus substitute with concomitant ACI. The polyurethane scaffold 
was designed for the clinical challenge of treating patients with irreparable, partial 
meniscal lesions, in an attempt to provide pain relief and restore meniscus function. 
However, a relatively high failure rate (23-47%) has been noted for the substitute at 
midterm follow up 83,256. Generally, advanced chondral degeneration represents the 
most common contraindication for meniscus replacement with a scaffold 257. In our 
present study, eight patients in the Actifit® group had good midterm clinical outcomes 
without any revision surgery or knee arthroplasty. The evaluation of postoperative MRI 
on Actifit® scaffold showed well retained morphology at short-term follow-up and less 
intensive signal change at longer-term follow-up. Our results suggest that if the 




longer meniscal substitute survival could be achieved. 
For the first eight patients who had combined ACI and MAT in our previous short-term 
follow-up study 250, three were considered to have failed at a relatively early stage, 
having undergone total knee replacement at 2, 3 and 8 years post-graft. However, the 
other five patients remained physically active in the long-term (up to 20 years). The 
common characteristic of the six failure cases in the MAT group for the present study 
was obesity (mean BMI 30.07 ± 3.24 kg/m2). Jiménez-Garrido et al (2019) reported 
that obese patients (BMI ≥ 30 kg/m2, with four patients a BMI ≥ 30) had higher rates 
of meniscal transplant failure compared with non-obese patients, while non-obese 
patients had better knee functional scores compared with obese individuals. The high 
BMI of at least four of our MAT patients may therefore have contributed to the failure 
of their procedure. On the other hand, only one of our Actifit® patients had a BMI over 
30 (BMI = 30.5). 
Other previous studies have reported mid- to long-term clinical outcomes of MAT 
combined with ACI and demonstrated a sustained improvement of knee symptoms and 
function after a mean of 4.5 and 7.9 years follow-up 248,249. The reported failure rate in 
these studies were 11% and 33% respectively, with a mean survival time (failure cases) 
of less than 2 years and 5.4 years post-operatively. Our study of MAT combined with 
ACI had a comparable failure rate (30%) at longer follow-up and with patients who had 
a higher rate of bipolar cartilage lesions. Both previous studies suspected that the 
presence of bipolar lesions could predispose to failure, but these studies had small 
numbers and were inadequately powered to show any statistical differences. In our 
study, four out of the six failure cases presented with bipolar lesions, while five out of 
the 14 non-failed MAT group of patients presented with bipolar lesions; hence the 




combined procedure. However, further investigation with a larger sample size will be 
needed before firm conclusions can be drawn.  
Our multilevel modelling analysis showed that baseline Lysholm Score (pre-operative) 
had a significant positive correlation with post-operative score. Our group’s previous 
study identified pre-operative Lysholm score also as a factor influencing the likelihood 
of ACI patients progressing to arthroplasty in a cohort of 170 ACI-treated patients 99. 
Such predictors can be incorporated into predictive tools such as ORKA (Oswestry Risk 
of Knee Arthroplasty, a validated application, https://www.ork.app/) 99 which can be 
used to help surgeons and patients evaluate the risks and benefits of surgery, as well as 
improve planning for post-operative rehabilitation. 
Meniscal extrusion is the most commonly reported complication following meniscus 
transplantation 259,260. Results from our study indicated that a certain degree of meniscal 
extrusion in both groups was observed without significant differences at midterm 
radiological assessment. However, the Actifit® group tended to have a higher cartilage 
coverage on the sagittal plane compared to the MAT group. This could be explained by 
the fact that the anterior and posterior roots of the original meniscus are well preserved 
in meniscus scaffold implantations 257. In contrast, the Actifit® substitute implantation 
group tended to have poorer cartilage coverage in the coronal plane. This finding has 
similarly been reported in other studies 259,261. Faivre et al. 259 suggested that the pre-
operative coronal absolute meniscus extrusion strongly predicts post-operative 
meniscus morphological outcomes. Even though the meniscus extrusion is an important 
outcome measure in meniscus transplantation procedure, the whole joint status 
evaluation and chondroprotective effect would be more meaningful assessments to 
investigate the benefits of the implants in long-term follow-up. 




of patients may introduce a bias in building a multilevel model. Secondly, the fact that 
most of our cases had multiple pre-operative, concomitant or post-operative procedures, 
including microfracture, ACL reconstruction, osteotomy, is likely to complicate the 
data interpretation. Further, many of our patients had complex medical histories. These 
additional factors make it difficult to isolate the precise clinical effectiveness of 
concomitant MAT or Actifit® with ACI over time. To evaluate a series of combined 
procedures sufficient statistical power to achieve narrow confidence intervals, it is 
likely that a multicentre study will be required.  
In conclusion, our study shows for the first time that combining ACI with MAT or 
Actifit® partial meniscus replacement to treat patients with cartilage defects and 
meniscal deficiency can provide successful clinical outcomes, with 10-year survival 
rates of 71% in the MAT group and 100% in the Actifit® group. No significant 
differences were found between the two groups in terms of clinical and radiographic 
outcome, though this might be due to the limited patient numbers in the Actifit® group.  
Together our findings suggest that these combined surgical treatments might delay or 
prevent knee OA progression, essentially retaining a biological knee which is 
particularly relevant in young adult patients. The 30% failure rate noted in the MAT 
treatment group might relate to the patients’ high BMI, low pre-operative Lysholm 
score or number of cartilage lesions, all which have been indicated to have a negative 
effect on the outcome. In addition, 43% of patients required subsequent arthroscopic 
procedures, which needs to be discussed between the surgeon and patient to manage 








7.1 The role the meniscus plays in progression of knee OA 
Meniscus tears are normally caused by an acute injury or as a result of age-related 
meniscus degeneration, which is considered a significant contributor to knee OA 
pathology. However, the exact role the meniscus plays in this pathology is still not clear. 
Many studies have shown that the  meniscus is not only a critical mechanical support 
in the joint, but also has a profound biological influence on the onset and progression 
of knee OA262,263. 
In terms of the role as a “mechanical supporter”, the meniscus distributes loading across 
the articular surface of the knee joint and maintains the balance of the joint’s 
biomechanics. Extrusion or deficiency of the meniscus, leading to knee malalignment, 
was found to be significantly associated with the occurrence and enlarging of bone 
marrow lesions which closely correlated with the incidence and progression of knee 
OA 264,265. In support of this, patient B in our case report (chapter 1.4.6), who was 
treated with combined chondrocytes and BM-MSCs and implantation of an Actifit® 
meniscus scaffold, showed a gradual decrease in the size of BMLs over time. Gait 
analysis studies report that partial meniscectomy could cause subtle reduction in range 
of motion, increased external tibial rotation and axial force which leads to altered 
loading in certain regions of the tibial plateau and subsequent deterioration of the 
cartilage 266,267. However, due to the complexity and heterogeneity of knee-to-knee 
variability, the mechanisms driving different patient outcomes and affecting different 
locations of the joint after meniscectomy have yet to be fully identified. Patient based 
studies, cadaveric models, in vivo animal models and bioreactor models which are 
designed to investigate the meniscus mechanics and mechanobiology have their own 
advantages and disadvantages, while statistically augmented computational models are 




that predispose the knee joint to rapidly develop OA 268. 
From the perspective of being a “biological peacemaker” in the joint, meniscal injury 
and degeneration can affect the balance of the joint’s biologic environment. When an 
injured meniscus is exposed to a chemical stimulator or mechanical loading, the cells 
within it can produce pro-inflammatory cytokines, chemokines and matrix-degrading 
enzymes, potentially leading to ECM breakdown in meniscus, cartilage and synovium 
during OA pathogenesis. Interleukin-1β (IL-1β) and IL-6 are important pro-
inflammatory cytokines with increased levels in synovial fluid during early and late 
stage knee OA 269. Meniscal cells stimulated with pro-inflammatory cytokines have 
been shown to increase catabolic gene expression, production of MMPs, components 
of the NF-kB and tumour necrosis factor (TNF) family and decrease collagen and 
connective tissue growth factor (CTGF) gene expression 270. In our OA meniscus 
characterisation study (chapter 3), we found the decreased vascularity within the 
transverse collagen “tree” fibres and increased integrin cells surface markers on 
meniscal cells at P0 and P2, were associated with increased meniscal degeneration. All 
these factors may contribute to the inhibition of the intrinsic healing response of the 
meniscus. Likewise, an increased catabolic activity and degradative enzyme activity 
were found in the synovial fluid of patients with teared meniscus 263 and cartilage 
explants exposed to pro-inflammatory mediators 271. Hence, the biologic interactions 
between meniscus, synovial tissue and articular cartilage can synergistically exacerbate 





7.2 The clinical perspective: translation of meniscus 
regeneration research to clinical practice 
The key challenge in the clinic for the treatment of meniscal lesion is the limited ability 
of the injured meniscus for repair. Factors which contribute to this low or absent self-
repair capacity, particularly in the avascular region include poor intrinsic vascularity, 
hypocellularity, the presence of inflammatory mediators and various proteases in the 
synovial fluid, as well as complex mechanical loading 201. The use of a cell-based 
strategy for repair or regeneration of the meniscus has great potential, with cells 
responding to ‘damaged meniscus signals’ and actively responding and altering their 
metabolic activity to repair the lesions 272. A majority of pre-clinical research models 
have declared the benefits of using MSCs or allogeneic cells for meniscus tissue 
engineering 85. However, to our knowledge, there appears to be only two MSC injection 
trials 273,274, two micro-fragmented adipose tissue injection trials using Lipogems® 
275,276 and one meniscal cell bandage trial reported 105 with none showing clear clinical 
efficacy to date.  
7.2.1 Major obstacles limiting cell therapy for meniscus repair in the clinic 
The first limitation preventing the successful translation of the technologies is the 
various scaffolds as reviewed in chapter 1. Although all the studies showed a superior 
role of cell and scaffold combinations compared to acellular scaffolds, none of these 
studies compared different scaffolds with each other. Decellularised scaffolds are 
limited by their clinical GMP applicability 277. More studies are required to compare 
the efficacy of using cell-scaffold combinations with the injections of cells alone. In 
addition, to apply autologous cells seeded on a scaffold, requires in vitro cell expansion 
and availability of a GMP-approved cell therapy facility. The provision and governance 




investment. The second limitation is that there is no consensus on which cell type has 
shown the most promising results. Synovial MSCs 278 and adipose-derived MSCs 112 
have both demonstrated to having high proliferation rates and multilineage 
differentiation capacity. BM-MSCs have been a popular cell source in many studies, 
having the capability to respond and inhibit inflammation locally as we discussed in the 
two cases reported with autologous chondrocytes and BM-MSCs treated cartilage 
defect (chapter 1.4.6). However, harvesting of BM-MSCs can be a painful process and 
the cells have limited expansion potential in vitro 279. In our study, we demonstrate that 
autologous meniscal cells derived from discarded meniscectomy tissue could be a 
potential cell source (chapter 5). There is no ideal source of cells, with each type having 
certain advantages and disadvantages. In addition, the literature shows varying 
differentiation capacities between cell sources using different models and there is lack 
of evidence to prove one cell type superior to another in meniscal regeneration. The 
third limitation we have identified is the pathology of the injury model used in research 
not being comparable to the real ‘pathology’ process in humans. In research injury 
models such as the sheep explant defect model we used in chapter 5, the treatments are 
introduced immediately or within two weeks after the defects are created in the 
meniscus. In addition, the explant model is an isolated tissue, which is not incorporated 
to adjacent tissues with interconnecting vascularity and no loading is applied as seen in 
the in vivo situation. In clinical practice, patients normally receive the treatment several 
months or years after trauma, which leads to a different regeneration rate in chronic 
meniscal lesions compared with acute injuries. Therefore, the development of chronic 
meniscal injury models, which could reflect the human pathology would be a distinct 
advantage to help to provide better insights for developing clinically useful regenerative 




7.2.2 Future perspectives of translating cell-based meniscus tissue engineering to 
the clinic 
To achieve a promising meniscal cell therapy for clinical use in the near future, a single-
stage procedure using minimally manipulated autologous cells combined with a 
clinically approved, off-the-shelf meniscus scaffold is likely to represent the fastest 
option for clinical translation. Moreover, meniscus injury frequently presented with 
cartilage lesions in the daily clinic. Our clinical study in chapter 6 demonstrated the mid 
to long term benefit of using combined meniscus transplantation and ACI to treat co-
lesion patients. Therefore, addressing both lesions in cartilage and meniscus with cell-
based strategy for the treatment in a single procedure could be an ideal combination in 
the future. However, in the longer term, perhaps a more cost-effective cell-based 
meniscal therapy would be the use of an allogeneic approach, although further pre-
clinical study is required to demonstrate the safety of this approach. Unlike ACI for 
cartilage repair where the treated site has subchondral bone as a base and a collagen 
membrane can be attached as a cover to hold implanted cells in the lesion, the meniscus 
is an irregularly shaped piece of loosely attached fibrocartilage in the knee joint cavity. 
Any implanted cells may diminish quickly via joint effusion and inflammatory cytokine 
influences which may be likely to occur after any surgical procedure. Therefore, a 
clinically approved hydrogel like Tisseel® which could hold cells within a scaffold in 
the initial post-operative stage and facilitate cell retention and proliferation to enhance 
matrix formation is essential in the real clinical scenario. In this study we have 
identified meniscal progenitors in both avascular and vascular regions of the human 
meniscus, which could be considered as ideal therapeutic cell sources for meniscus 
tissue engineering. In addition, the  work described in this thesis which identified the 




alternative regenerative approaches whereby endogenous progenitors are targeted using 
biologic augmentation approaches, including mechanical stimulation, injection of 
platelet-rich plasma and autologous MSCs 280. 
7.3 Conclusion 
In this PhD work, we firstly demonstrated the exclusive cell surface markers (CD49b, 
CD49c and CD166) to distinguish cells phenotype from avascular or vascular meniscus 
and cartilage in the OA joint. We also discovered the meniscus “tree-like” collagen 
fibres pathological changes in degenerated meniscal tissue. The meniscal cells derived 
from OA meniscus had been approved its chondrogenic capacity in vitro. These results 
filled the gap in the pathology changes in meniscus degeneration and implied the 
potential treatment target in the future.  
Secondly, our study demonstrated that the human meniscus contains meniscal 
progenitor populations in both the avascular and vascular regions. The vascular 
progenitor population exhibit better stromal cell characteristics which likely associate 
with the superior meniscal healing potential in the vascular region. These findings 
suggested that meniscal progenitors represent and attractive novel cell therapy strategy 
for the enhancement of meniscal repair and regeneration. 
Thirdly, this study proved the feasibility of using fibrin gel to deliver autologous 
avascular meniscal cells in a clinical grade meniscus substitute in vitro. Cells delivered 
by fibrin gel showed an increased cell proliferation and more matrix production within 
the scaffold compared to cells directly seeded into the scaffold in the absence of fibrin. 
The results of the experiment represent the foundation of this approach of augmenting 





Lastly, the clinical work demonstrated the combining ACI with MAT or Actifit® partial 
meniscus replacement to treat patients with cartilage defects and meniscal deficiency 
can provide successful clinical outcomes, with 10-year survival rates of 71% in the 
MAT group and 100% in the Actifit® group.  
Together, this PhD work presented a comprehensive investigation in meniscus-related 
research, including meniscus degeneration, meniscal progenitors and cell-based 
meniscus tissue engineering. This study filled in the gaps of current meniscal biology 
and pathology, as well as providing a novel cell-based meniscus tissue regeneration 
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